

Curriculum Vitae

LOUIS M. ALEDORT, M.D.

Date of Birth: December 28, 1934

Marital Status: married, 2 children

Home Address:

300 Central Park West, #3H
New York, New York 10024

Office Address:

Louis M. Aledort, MD
The Mary Weinfeld Professor of Clinical Research in Hemophilia
Mount Sinai School of Medicine
One Gustave L. Levy Place, Box 1006
New York, NY 10029-6574
Tel.: 212.241.7971
Fax: 212.987.3326
louis.aledort@mountsinai.org

Education & Training:

| | |
|---|-----------|
| Queens College of the City of New York, Bachelor of Science, Chemistry | 1951-1955 |
| Albert Einstein College of Medicine, Bronx, New York Doctor of Medicine | 1955-1959 |
| Intern, Internal Medicine, University of Virginia Hospital | 1959-1960 |
| Resident, Internal Medicine, University of Virginia | 1960-1961 |
| Associate Resident in Internal Medicine, Strong Memorial Hospital, Rochester, New York | 1963-1964 |
| Hematology Fellowship, Strong Memorial Hospital, Rochester, New York | 1964-1966 |

Licensure:

Licensed to practice medicine in the State of New York
New York State License #90221 Date issue: January 1, 1966
Certification, Board of Hematology #24532, 1972
Certification, Board of Internal Medicine #24532, 1966

Other Academic Positions:

| | | |
|----------------------|--|--|
| 1961-1963 Raphael | NIAMD, Bethesda, Maryland | Clinical Associate with Dr. Shulman, Hematology Division (USPHS Sr. Asst. Surgeon) |
| 1964-1966 | University of Rochester Rochester, New York | Instructor in Medicine Medical School, Fellow in Hematology, Associate Physician |
| 1966-1967 | The Mount Sinai Hospital, New York, New York | Research Assistant in Hematology |
| 1966-1967 | Mount Sinai School of Medicine New York, New York | Associate in Medicine |
| 1967-1973 | Mount Sinai School of Medicine New York, New York | Assistant Professor in Medicine |
| 1967-1973 | Mount Sinai School of Medicine New York, New York | Assistant Attending in Medicine |
| 1973-1979 | Mount Sinai School of Medicine New York, New York | Associate Professor in Medicine |
| 1973-1979 | Mount Sinai School of Medicine New York, New York | Associate Attending in Medicine |
| 1975-1988 | Mount Sinai School of Medicine New York, New York | Vice Chairman, Dept. of Medicine |
| 1979 | Mount Sinai School of Medicine New York, New York | Professor in Medicine |
| 1979 | Mount Sinai School of Medicine New York, New York | Attending in Medicine |
| 1979 | Cornell University Medical College New York, New York | Adjunct Professor in Medicine |
| 1988-1994 | Mount Sinai School of Medicine New York, New York | Dean for Faculty & Hospital Affairs |
| 1993-present | Mount Sinai School of Medicine New York, New York | The Mary Weinfeld Professor of Clinical Research in Hemophilia |
| 1999-present | New School University | Scientist-in-Residence |

Major Positions:

| | |
|-----------|--|
| 1966-1978 | Director, Coagulation Laboratory, The Mount Sinai Hospital, New York |
| 1966-1976 | Director, Student Health, Mount Sinai School of Medicine, New York |
| 1969-1983 | Medical Director, National Hemophilia Foundation |
| 1970-1980 | Medical Secretary, World Federation of Hemophilia |

1972-1997 Director of International Hemophilia Training Center at Mount Sinai School of Medicine, New York

1974-1979 Executive Secretary, Policy Board, Persantine Aspirin Refraction Study

1975-1983 American Society of Hematology, Public Information Committee

1975-1985 Advisory Panel, House, Ways and Means Committee on National Health Insurance

1975-1983 Permanent Seat, American Blood Commission

1975-1977 Vice President, American Blood Commission

1975-1980 Panel on Review of Blood and Blood Derivatives, FDA panel member

1975-1980 Executive Committee, American Blood Commission

1977-1980 Medical Advisory Board, American National Red Cross

1978-1979 Secretary, American Blood Commission

1978-1983 Plasma and Plasma Products Committee, American Blood Commission

1980-1986 Blood Consultant, World Health Organization

1980-1984 Executive Secretary, Policy Board, Persantine Aspirin Refraction Study II

1982-1986 Clinical Practice Committee, American Society of Hematology

1983-1993 Chairman, Committee on Practice, American College of Physicians

1983- Member, Board of Directors, Scientific Advisory Committee, Vice President, Irvington Institute for Immunological Research

1984-1986 Chairman, International Hemophilia Training Centers of the World Federation of Hemophilia

1986-1988 Vice President, Faculty Practice Associates, Mount Sinai School of Medicine

1986- Co-Chairman, International Congress on Thrombosis and Hemostasis, Subcommittee on Factor VIII & IX

1986- Member, International Congress on Thrombosis and Hemostasis, Subcommittee on von Willebrand's Disease

1987-1993 Chairman, Committee of Practice, American Society of Hematology

1987-1988 Public Education Committee, American Society of Hematology

1988-1993 Member, Committee on Public Information and Governmental Affairs, American Society of Hematology

1990-1993 Member, Committee on Practice, American College of Physicians

1993- Chairman, Fellowship Committee, Irvington Institute for Immunological Research

1994- Member, Education Committee, American Society of Hematology

1994-1998 Medical and Scientific Advisory Committee, World Federation of Hemophilia

1994- Editorial Advisory Board, Hemophilia

1995- Member, Advisory Board, Maternal and Child Health Bureau, HHS

1996- Scientific Advisor, American National Red Cross

1997-2011 Member, Professional Advisory Committee, Visiting Nurse Service of New York

1997- Member, Medical and High Tech Advisory Committee, Visiting Nurse Service of New York

1997- Member, Scientific Advisory Committee, Nabi

1997- Member, Scientific Advisory Committee, Novo Nordisk Pharmaceuticals, Inc.

1995-2000 Member, Borough of Tenafly (NJ) Department of Health

1998-2000 President, Borough of Tenafly (NJ) Department of Health

2000-present Councilor, American College of Physicians-American Society of Internal Medicine, Downstate I Manhattan North Council

2000-present District President, American College of Physicians-American Society of Internal Medicine, Downstate I Manhattan North

2003-present Member, Editorial Board, *Current Hematology Reports*

2003-present Member, Board of Governors, Eugene Lang College of New School University

2003-2006 Member, Editorial Board, *American Journal of Hematology*

2007-2010 Associate Editor, *Haemophilia*

2008-present Member, Editorial Advisory Panel, *Expert Review of Hematology*

2009-2012 Member, Editorial Board, Thrombosis

2009-present Member, Editorial Board, *Case Reports in Medicine*

2009-present Associate Editor, *Journal of Thrombosis and Haemostasis*

2009-present Member, Editorial Board, *American Journal of Hematology*

Professional Activities:

1969-1970 President, Albert Einstein College of Medicine Alumni
1970-1972 Alumni Council, Yeshiva University
1972-1983 Testify before:
House, Ways and Means Committee
Senate and House Health Subcommittee
Foreign and Interstate Commerce Committee
1972 Hemophilia Liaison to WHO
1972-1973 Task Force, NHLI - Coagulation
1972-1973 Task Force on Medically Important Problems, NIGMS
1974-1975 Ad Hoc Committee for Establishment of American Blood Commission, HEW
1974-1975 Task Force on Synthesis of Factor VIII, NHLI
1974-1975 Task Force on Factor VIII Inhibitors, NHL
1974-1975 Task Force on Factor IX, FDA/NHLI
1974-1975 Task Force on Animal Models, National Academy of Sciences, NRC, ILAR
1974-1975 Coordinator, Workshop on VIII-Carrier Detection, NHLI
1974-1978 Chairman, Committee on International Conservation of Blood Resources, WFH
1974-1975 Factor VIII Subcommittee of the International Society on Thrombosis and Hemostasis
1975-1976 Coordinator, Hemophilia Education Program, NHLI/OPCE
1976-1976 New York Advisory Committee, ACP-Governor Downstate Region 1
1976-1976 Chairman, Workshop on Complications of Hemophilia, NHLI, FDA, NHF
1976-1976 Advisory Committee, Public Law #94-63, HSA
1976-1976 Advisory Committee, Implementation of Public Law #94-31, NHLI
1976-1980 Standing Committee on Blood and Blood Component Utilization, ABC
1976-1977 Hematology Consultant, PSRO
1976-1976 Member, Technical Advisory Board of the Booz-Allen Hemophilia Study
1976-1977 Member, Advisory Board of the HSA Hemophilia Program
1979-1981 Search Committee, University of Rochester, Hemophilia Center Medical Director
1979-1981 Search Committee, NHF Executive Director
1979-1988 Editorial Advisory Board, Primary Cardiology
1979-1983 US/USSR Exchange Program - Problem Area 6, NHLBI
1981-1984 Member, Genetic Disease Review and Advisory Committee of the HSA
1981-1985 Member, Blood Diseases and Resources Advisory Committee of the NHLBI
1981-1986 Member, Expert Advisory Panel on Human Blood Products and Related Substances
1982-1992 Editorial Advisory Board, Hospital Practice
1982-1986 Secretary of Health Task Force on Auto Immune Deficiency Syndrome (AIDS)
1983-1986 Editorial Board, AIDS Research
1983- NHLBI Task Force on Auto Immune Deficiency Syndrome (AIDS)
1984-1987 Member, ICTH Subcommittee on Factor VIII and von Willebrand Factor
1985-1990 Member, Committee on Health and Public Policy
1986-1990 Working Group, Medical, Social and Health Policy Implications of Screening Tests for Anti-HIV, AIDS Institute
1987- Subcommittee on vWF, ICTH
1987- Subcommittee on Factor VIII and IX, ICTH
1987- Consultant Field Reader, Office of Orphan Products Development, Department of Health and Human Services
1987- Member, Local Arrangements Committee of the American College of Physicians.
1989- Member, Legislation Committee of the American Society of Internal Medicine
1994- Member, Subcommittee on Factor VIII and IX, International Society on Thrombosis and Hemostasis
1994- Member, Medical Advisory Board, World Federation of Hemophilia

- 1994- Data Monitoring Committees:
 PARIS Study
 Recombinant VIII (Chairman)
 PCR for Biologics
 Activated Prothrombin Complex Materials for the Treatment of Antibodies
 HIV Vaccine and Viral Titres
 Factor IX Products and Viral Safety in PUPs
- 1996- Member, Internal Advisory Committee, Gene Therapy Hemophilia B
- 2001 Frederick Stohlman Jr. MD Visiting Professor, St. Elizabeth's Medical Center of Boston
- 2001-present Member, Program Coordinating Committee, American College of Physicians
- 2002-present Member, Editorial Board, *Thrombosis Journal*
- 2002-present Member, Editorial Board, *Current Hematology Reports*

Professional Membership:

- 1968- American Society of Hematology, #52724
- 1968- New York Society for the Study of Blood
- 1968- International Society of Hematology
- 1968- American Physiological Society
- 1970- Fellow of the American College of Physicians, #00017342
- 1971- Council on Thrombosis, American Heart Association
- 1976- American Association for the Advancement of Science

Review for Following Journals:

- Proceedings of the Society for Experimental Biology and Medicine
- Blood
- Circulation
- Medical Letter
- Journal of Laboratory and Clinical Medicine
- Thrombosis Research
- Annals of Internal Medicine
- American Journal of Cardiology
- New England Journal of Medicine
- American Journal of Medical Genetics
- Thrombosis and Hemostasis
- Mount Sinai Journal
- American Dental Assistants Association
- American Journal of Medicine
- Journal of Infectious Diseases
- Haemophilia – Editorial Board Member
- Hematology International Journal
- Thrombosis and Hemostasis: Research
- Journal of Blood Transfusion and Hematopathology

Awards and Honors:

- 1983 Alpha Therapeutic Award
- 1984 Mount Sinai School of Medicine, Department of Medicine Service Award
- 1984 NHF Murray Thelin Science Award
- 1986 Festschrift, presented by NHF, proclaimed "Lou Aledort Day"
- 1990 Mount Sinai Medical Center, Dept. of Nursing Life Time Achievement Award
- 1991 Solomon Berson Award
- 1998 Tribute Symposium: National, Cultural, and Economic Considerations Affecting Diagnostic and Treatment Practices in Hemophilia Throughout the Americas: A Pan-Caribbean Conference; San Juan, Puerto Rico
- 2004 Mastership, American College of Physicians
- 2005 Laureate Award, American College of Physicians, NY Chapter
- 2010 Lifetime Achievement Award, Hemophilia and Thrombosis Research Society (HTRS)

- 2011 Lifetime Achievement Award, Albert Einstein College of Medicine
- 2014 Honorary Doctorate Degree- Lund University
- 2019 Humanitarian Award - University of Rochester

Academic Activities:

- Transfusion Committee
- Patient Care Committee
- Internship Committee
- Semi-Private Committee
- Attendings Committee
- House Staff Integration Committee
- Medical Service Plan Advisory Council
- Academic Council Committee on Promotions (Medical Students)
- Unit Management
- Search Committee for Spinal Cord Injury Center (Bronx VA)
- VA Dean's Committee
- Academic Council Committee on Promotions
- Chart Review Committee
- House Staff Evaluation Committee
- Ward Billing Committee
- Private Ambulatory Care Model
- Patient Scheduling Committee
- Nurse Retention and Recruitment Task Force
- Ad Hoc Subcommittee to Review Use of 10% Special Fund
- Ad Hoc Committee on Research and Educational Resources
- Ad Hoc Committee to Review Anesthesiology Residency Program
- Surveillance Committee
- Clinical Standards Committee
- Clinical Advisory Committee
- Code of Behavior Committee
- Teaching Committee
- Moonlighting Committee
- Executive Committee of the Association of the Attending Staff
- Evidence-based teaching

Bibliography

1. Millichap JG, Aledort LM, Madsen JA. A critical evaluation of therapy of febrile seizures. *J Pediatr* 1960; 56: 3: 364-368.
2. Millichap JG, Madsen JA, Aledort LM. Studies in febrile seizures: V. clinical and electroencephalographic study in unselected patients. *Neurol* 1960; 10: 7:643-653.
3. Shulman NR, Marder VJ, Aledort LM, Hiller MC. Complement-fixing isoantibodies against antigens common to platelets and leukocytes. *Trans Assoc Am Physic* 1962; 75: 89-98.
4. Shulman NR, Marder VJ, Aledort LM, Hiller MC. Isoantibodies against platelets and leukocytes. *Proc Soc Blood Transf* 1964; 439-447.
5. Moss AJ, Aledort LM. Use of Edrophonium (Tensilon) in the Evaluation of Supraventricular Tachycardias. *Am J Cardiol* 1966; 17: 58-62.
6. Aledort LM, Hodges M, Brown JA. Irreversible Renal Failure Due to Malignant Lymphoma. *Ann Intern Med* 1966; 65: 1: 117-121.
7. Aledort LM, Weed RI, Troup SB. Ionic Effects on Firefly Bioluminescence Assay of Red Blood Cell ATP. *Analyt Biochem* 1966; 17: 2: 268-277.
8. Weiss HJ, Aledort LM. Impaired platelet/connective-tissue reaction in man after aspirin ingestion. *Lancet* 1967; 495-497.
9. Aledort LM, Lord GP. Idiopathic Pulmonary Hemosiderosis: Severe Anemia Without Hemoptysis - One Year Follow-Up of Pulmonary Function. *Arch Intern Med* 1967; 120: 220-223.
10. Aledort LM, Troup SB, Weed RI. Inhibition of Sulfhydryl-Dependent Platelet Functions by Penetrating and Non-Penetrating Analogues of Parachloromercuribenzenes. *Blood* 1968; 31: 4: 471-479.
11. Aledort LM, Niemetz J. Dissociation of Platelet Aggregation from Clot Retraction, Potassium Loss, and Adenosine Triphosphatase Activity. *Proc Soc Exp Biol Med* 1968; 128:658-661.
12. Weiss HJ, Aledort LM, Kochwa S. The Effect of Salicylates on the Hemostatic Properties of Platelets in Man. *J Clin Invest* 1968; 47: 9: 2169-2180.
13. Aledort LM, Hirsch C, Udkow M, Puszkin E. Effect of Anticoagulants on Calcium and Magnesium Content of Human Platelets. *Transfusion* 1969; 9: 4: 212-213.
14. Puszkin E, Aledort LM, Puszkin S. Human Platelets: Amino Acid Synthesis. *Proc Soc Exp Biol Med* 1969; 131: 957-959.
15. Puszkin E, Aledort L, Puszkin S. The labeling of dicarboxylic amino acids and their amides by glucose and acetate in human platelets. *J Lab Clin Med* 1970; 75: 2: 234-243.
16. Puszkin E, Puszkin S, Aledort LM. Colchicine-binding Protein from Human Platelets and Its Effect on Muscle Myosin and Platelet Myosin-like Thrombosthenin-M. *J Biol Chem* 1970; 246: 2:271-276.
17. Aledort LM. The Management of Hemophilia: A Perspective. *Drug Ther* 1971; 1: 3: 55-59.
18. Aledort LM, Gilbert HS, Puszkin E. Patterns of Endogenous Platelet Serotonin Release. *Transfusion* 1971; 11: 5: 266-269.

19. Puszkin E, Gutfreund D, Aledort LM. Hemostatic Abnormalities in Heroin Addicts. *Transfusion* 1972; 12: 1: 9-11.
20. Goldman BA, Aledort LA [sic]. Essential Athrombia: A Family Study. *Ann Intern Med* 1972; 76: 2 :269-273.
21. Litwak RS, Jurado RA, Lukban SB, Mitchell BA, Kahn M, Berger S, Estioko MR, Aledort L. Perfusion without donor blood. *J Thorac Cardiovasc Surg* 1972; 64: 5: 714-728.
22. Burrows L, Haimov M, Aledort L, Leiter E, Nirmul G, Shanzer H, Taub R, Glabman S. The Platelet in the Obliterate Vascular Rejection Phenomenon. *Transplant Proc* 1973; 5: 1: 157-160.
23. Aledort LM, Puszkin S, Puszkin E, Hanson J, Katz AM. Control of Platelet Contraction. *Ser Haemat* 1973; 6: 3: 410-417.
24. Hanson JP, Repke DI, Katz AM, Aledort LM. Calcium ion control of platelet thrombosthenin ATPase activity. *Biochim Biophys Acta* 1973; 314: 382-389.
25. Berger S, Aledort LM, Gilbert HS, Hanson JP, Wasserman LR. Abnormalities of Platelet Function in Patients with Polycythemia Vera. *Cancer Res* 1973; 33: 2683-2687.
26. Puszkin S, Puszkin E, Katz AM, Aledort LM. Control of platelet actomyosin activity: effect of ADP on superprecipitation and ATPase activity of human platelet actomyosin. *Biochim Biophys Acta* 1974; 347: 102-112.
27. Aledort LM. Blood fractions for hæmophilia. *Lancet* 1974; 2: 1452.
28. Hearing before the Subcommittee on Health of the Committee on Labor and Public Welfare, United States Senate, Ninety-Third Congress, First Session on S.1326 (Hemophilia Act of 1973) to amend the Public Health Service Act to provide for programs for the diagnosis and treatment of hemophilia, November 15, 1973 (Testimony of Louis M. Aledort, MD) 1974, 22-25.
29. Aledort LM, Gilbert MS, Rapaport SI. Introduction: Recent Advances in Hemophilia. *Ann NY Acad Sci* 1975; 240: 5-6.
30. Walsh PN, Rizza CR, Evans BE, Aledort LM. The therapeutic role of epsilon aminocaproic acid (EACA) for dental extractions in hemophiliacs. *Ann NY Acad Sci* 1975; 240: 267-276.
31. Aledort LM (ed). Recent Advances in Hemophilia. *Ann NY Acad Sci* 1975; 240: 1-426.
32. Tamari Y, Aledort L, Puszkin E, Degnan TJ, Wagner N, Kaplitt MJ, Pierce EC II. Functional Changes in Platelets During Extracorporeal Circulation. *Ann Thorac Surg* 1975; 19: 6: 639-647.
33. Benis AM, Nossel HL, Aledort LM, Koffsky RM, Stevenson JF, Leonard EF, Shiang H, Litwak RS. Extracorporeal Model for Study of Factors Affecting Thrombus Formation. *Thrombos Diathes Haemorrh* 1975; 34: 1: 127-144.
34. Aledort LM. Animal research and the shrinking dollar. *J Lab Clin Med* 1975; 86: 6: 899-900.
35. Gorlin R, Aledort LM. Stop the Clot, Stop the Infarction. *Prim Cardiol* 1975; 1: 3: 4.
36. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J.

- A More Uniform Measurement of Factor VIII Inhibitors. *Thrombos Diathes Haemorrh* 1975; 34: 869-872.
37. Aledort LM. Can a National All Voluntary Blood Transfusion Service by Adequate Blood Component Therapy Cover Actual and Future Needs of AHF? *Vox Sang* 1976; 31: 296-297.
 38. Patel I, Aledort L, Puszkin EG. Amino Acid Metabolism of Platelets in Leukemia. *Cancer Res* 1976; 36: 1263-1266.
 39. Aledort LM. Platelets and Thromboembolism. *Thromb Plate Anticoag* 1976; 2: 156-165.
 40. Aledort LM. Anticoagulant Drugs: When to Use - and How. *Primary Cardiol* 1976 ;2: 38-40.
 41. Aledort LM. Anti-Platelet Drugs: Newest in Anticoagulant Therapy. *Primary Cardiol* 1976; 2: 34-37.
 42. Supplemental Hearing before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-Fourth Congress, Second Session on H.R. 12937, H.R. 14309, and H.R. 14822 (identical bills), bills to establish a national system of maternal and child health care, and H.R. 14497, a bill to establish a national health insurance system for maternal and child health care, September 13, 1976 (Maternal and Child Health Care Act, 1976) (Testimony of Louis M. Aledort, MD) 1976; 250-256.
 43. Ambrose JA, Aledort LM. Human model for the study of abnormal platelet function in atherosclerotic heart disease. *Am J Cardiol* 1976; 38: 667-668.
 44. Aledort LM, Grupenhoff JT. Legislative Considerations for Studies with Animal Models. *Animal Models of Thrombosis and Hemorrhagic Diseases*, DHEW Publication No. (NIH) 76-982. NIH 1976; 159-165.
 45. Klein HG, Aledort LM, Bouma BN, Hoyer LW, Zimmerman TS, DeMets DL. A co-operative study for the detection of the carrier state of classic hemophilia. *N Engl J Med* 1977; 296: 959-962.
 46. Aledort LM. Factor IX and thrombosis. *Scand J Haematol* 1977; 30(suppl): 40-42.
 47. Aledort LM. Home Care - An International Challenge. *Scand J Haematol* 1977; 30(suppl): 55.
 48. Aledort LM. World Use of Blood Products for Hemophilia. *Scand J Haematol* 1977;30(suppl): 56-57.
 49. Aledort LM. Methods of Care, Products Available, Complications of Therapy. *Mt. Sinai J Med* 1977; 44: 3: 332-338.
 50. Joint Hearing before the Subcommittee on Health Committee on Ways and Means and the Subcommittee on Health and the Environment Committee on Interstate and Foreign Commerce, U.S. House of Representatives, Ninety-Fifth Congress, First Session on H.R. 6575 Hospital Cost Containment Act of 1977, May 13, 1977 (Testimony of Louis M. Aledort, MD) 1977, 1074-1077.
 51. Aledort LM: Hematologic Management and Surgery in Hemophilia. *Mt. Sinai J Med* 1977; 44: 3: 371-373.
 52. Gilbert MS, Aledort LM (eds): Comprehensive care in hemophilia: a team approach. *Mt. Sinai J Med* 1977; 44: 3: 313-479.

53. Aledort LM: Epilogue. *Mt. Sinai J Med* 1977; 44: 3: 477-479.
54. Aledort LM: Anticoagulation with Coumarin Drugs. *Primary Cardiol* 1977; 3: 34-37.
55. Akhmeteli MA, Aledort LM, Alexaniants S, Bulanov AG, Elston RC, Ginter EK, Goussev A, Graham JB, Hermans J, Larrieu MJ, Lothe F, McLaren AD, Manucci [sic] PM, Prentice CRM, Veltkamp JJ. Methods for the detection of haemophilia carriers: a Memorandum. *Bulletin WHO* 1977; 55: 6: 675-702.
56. Aledort LM. When to Anticoagulate with Heparin. *Primary Cardiol* 1977; 3: 20-23.
57. Patel IP, Ambinder E, Holland JF, Aledort LM. In Vitro and In Vivo Comparison of Single Donor Platelets and Multiple-Donor Pooled Platelets Transfusions in Leukemic Patients. *Transfusions* 1978; 18: 1: 118-121.
58. Hearings before the Subcommittee on Health of the Committee on Ways and Means, House of Representatives, Ninety-Fifth Congress, Second Session , June 19, 22, 1978 (Amendments to the Medicare Program) (Testimony of Louis M. Aledort, MD) 1978; 359-360.
59. Evans BE, Aledort LM. Hemophilia and dental treatment. *JADA* 1978; 96: 827-834.
60. Gendelman S, Aledort L, Hollin S. Intracranial Meningioma in Factor IX Deficiency. *JAMA* 1978; 239: 8: 748-749.
61. Evans BE, Aledort LM. Inhibition of ejaculation due to epsilon aminocaproic acid. *N Engl J Med* (letter) 1978; 298: 3 :166-167.
62. Eyster ME, Gill FM, Blatt PM, Hilgartner MW, Ballard JO, Kinney TR, and the Hemophilia Study Group. Central Nervous System Bleeding in Hemophiliacs. *Blood* 1978; 51: 6: 1179-1188.
63. Lusher JM, McMillan CW, and the Hemophilia Study Group. Severe Factor VIII and Factor IX Deficiency in Females. *Am J Med* 1978; 65: 637-648.
64. Evans BE, Irving SP, Aledort LM. Use of microcrystalline collagen for hemostasis after oral surgery in a hemophiliac. *J Oral Surg* 1979; 37: 126-128.
65. Vlachakis ND, Aledort L. Platelet aggregation in relationship to plasma catecholamines in patients with hypertension. *Atherosclerosis* 1979; 32: 451-460.
66. Aledort LM. Heparin Dosage: Is It Disease Specific? *Prim Cardiol* 1979; 5: 8-10.
67. Aledort LM. Comprehensive Care of Hemophilia. *SE Asian J Trop Med Publ Health* 1979; 10: 2: 280-281.
68. Aledort LM. Problem of Abnormal Hemostasis in Liver Disease. *SE Asian J Trop Med Publ Health* 1979; 10: 3: 348-349.
69. Aledort LM. At Last - A National Blood Policy? *Hospital Practice* 1979; 14: 11-15.
70. Hearings before the Subcommittee on Health of the Committee on Ways and Means, House of Representatives, Ninety-Sixth Congress, First Session, June 18, 27, 1979 (Amendments to the Medicare Program) (Testimony of Louis M. Aledort, MD) 1979, 200-204.
71. Vlachakis ND, Aledort L. Platelet Lipid Peroxides as Determinant of Platelet Survival and Sympathetic Stimulation in Patients with Hypertension. *Biochem Med* 1979; 21: 94-103.

72. Kasper CK, and the Hemophilia Study Group. Effect of Prothrombin Complex Concentrates on Factor VIII Inhibitor Levels. *Blood* 1979; 54: 6: 1358-1368.
73. Vlachakis ND, Aledort L. Hypertension and Propranolol Therapy: Effect on Blood Pressure, Plasma Catecholamines and Platelet Aggregation. *Am J Cardiol* 1980; 45: 321-325.
74. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM, and the Hemophilia Study Group. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. *N Engl J Med* 1980; 303: 8: 421-425.
75. Persantine-Aspirin Reinfarction Study Research Group, The. Persantine and Aspirin in Coronary Heart Disease. *Circulation* 1980; 62: 3: 449-461.
76. Aledort LM: Working together: the secret to financial counseling in hemophilia (interview). *ECHO* 1980; 1: 5: 2-3.
77. Persantine-Aspirin Reinfarction Study Research Group. Persantine-Aspirin Reinfarction Study: Design, Methods and Baseline Results. *Circulation* 1980; 62: 3: III-42.
78. Aledort LM. The Availability of Plasma Products and the Care of Hemophilia Patients. *JAMA* 1981; 246: 2: 157.
79. Aledort LM. Introducing a New Series on Coagulation. *Prim Cardiol* 1981; 7: 11.
80. Aledort LM. Valvular Disease, Surgery, and Anticoagulation. *Prim Cardiol* 1981; 7: 10.
81. Aledort LM. Financing the Cost of Concentrates: The United States Experience. *Haemostasis* 1981; 10(suppl.1): 69-71.
82. Aledort LM. Lessons from hemophilia. *N Engl J Med* 1982; 306: 607-608.
83. Aledort LM. Principles of Anticoagulant Therapy: Guidelines for Prophylactic and Therapeutic Use. Recognition and Mgmt of Thromboemb Disorders 1982; 48-53.
84. Aledort LM. Letter to the editor. *N Engl J Med* 1982; 307: 556.
85. Aledort LM, Gorlin R. The Persantine-Aspirin Reinfarction Study. *Prim Cardiol* 1982; 8: 104-105.
86. Aledort LM. Effective Use of Anticoagulants. *Drug Therapy* 1982; 12: 107-117
87. Cederbaum AI, Blatt PM, Levine PH, and the Hemophilia Study Group. Abnormal Serum Transaminase Levels in Patients with Hemophilia A. *Arch Intern Med* 1982; 142: 481-484.
88. Aledort LM. Coagulation and Bleeding: The Physiologic Janus. *Hosp Prac* 1982; 17: 13-16.
89. Aledort LM. Current Concepts in Diagnosis and Management of Hemophilia. *Hosp Prac* 1982; 17: 77-92.
90. Hilgartner MW, Knatterud GL, and the FEIBA Study Group. The Use of Factor Eight Inhibitor By-Passing Activity (FEIBA Immuno) Product for Treatment of Bleeding Episodes in Hemophiliacs with Inhibitors. *Blood* 1983; 61: 1: 36-40.
91. Radensky PW, Sorett E, Schoenbaum EE, Aledort LM. Uncerative Colitis and Hemophilia A. *Mt. Sinai J Med* 1983; 50: 3: 268-269.

92. Aledort LM, Goodnight SH, Rao AV, Schwarz J, Whitehurst D, Shapiro SS, and Hemophilia Study Group. Impact of factor VIII deficiency on clotting factor utilization in the United States. *La Ricerca Clin Lab* 1983; 13: 33-41.
93. Aledort LM. A.I.D.S.: A 20th-Century Plague. *Prim Cardiol* 1983; 9: 15.
94. Aledort LM. What is the Prospective Impact of the Recombinant DNA Technique on the Production of Human Plasma Derivatives? Which are the Derivates Where Donor Plasma Could be Replaced? *Vox Sang* 1983; 44: 390-395.
95. Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warriar AI, Whitehurst DA. Autoplex Versus Proplex: A Controlled, Double-Blind Study of Effectiveness in Acute Hemarthroses in Hemophiliacs With Inhibitors to Factor VIII. *Blood* 1983; 62: 5: 1135-1138.
96. Aledort LM. The Bleeding Patient: A Systematic Approach to the Workup. *Diagnosis* 1984; 6: 87-90.
97. Smith PS, Levine PH, and the Directors of Eleven Participating Hemophilia Centers. The Benefits of Comprehensive Care of Hemophilia: A Five-Year Study of Outcomes. *Am J Pub Health* 1984; 74: 6: 616-617.
98. Aledort LM. Alternatives to Financing. *Scand J Haematol* 1984; 33(suppl 40): 455-457.
99. Aledort LM. Side Effects of Substitution Therapy. *Scand J Haematol* 1984; 33(suppl 40): 331-333.
100. Isola L, Forster A, Aledort LM. Desamino-D-Arginine Vasopressin and Bleeding Time in von Willebrand's Disease. *Ann Intern Med (letter)* 1984; 101: 5: 719-720.
101. Aledort LM. The Eye and the Organism. *Hosp Prac* 1984; 19: 14-15.
102. Aledort LM, Levine PH, Hilgartner M, Blatt P, Spero JA, Goldberg JD, Bianchi L, Desmet V, Scheuer P, Popper H, Berk PD. A Study of Liver Biopsies and Liver Disease Among Hemophiliacs. *Blood* 1985; 66: 2: 367-372.
103. Hilgartner MW, Aledort LM. AIDS in Hemophilia. *Ann NY Acad Sci* 1985; 437: 466-471.
104. Aledort LM, Gorlin R. Unexpected Recurrent Bleeding in Patient with Bjork-Shiley Prosthesis on Anticoagulants. *Prim Cardiol* 1985; 11: 156-161.
105. Jason J, Hilgartner M, Holman RC, Dixon G, Spira TJ, Aledort L, Evatt B. Immune Status of Blood Product Recipients. *JAMA* 1985; 253: 8: 1140-1145.
106. Johnson RE, Lawrence DN, Evatt BL, Bregman DJ, Zyla LD, Curran JW, Aledort LM, Eyster ME, Brownstein AP, Carman CJ. Acquired Immunodeficiency Syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. *Am J Epidemiol* 1985; 121: 6: 797-810.
107. Jason J, McDougal JS, Holman RC, Stein SF, Lawrence DN, Nicholson JKA, Dixon G, Doxey M, Evatt BL, and the Hemophilia/AIDS Collaborative Study Group. Human T-Lymphotropic Retrovirus Type III / Lymphadenopathy-Associated Virus Antibody. *JAMA* 1985; 253: 23: 3409-3415.
108. Eyster ME, Whitehurst DA, Catalano PM, McMillan CW, Goodnight SH, Kasper CK, Gill JC, Aledort LM, Hilgartner MW, Levine PH, Edson JR, Hathaway WE, Lusher JM, Gill FM, Poole WK, Shapiro SS. Long-Term Follow-Up of Hemophiliacs with Lymphocytopenia or Thrombocytopenia. *Blood* 1985; 66: 6: 1317-1320.

109. Aledort LM. The Current Status of Transfusion Therapy. *AIDS Center News* 1985; 2: 4: 1-2.
110. Markova I, Forbes CD, Aledort LM, Inwood M, Mandalaki T, Miller CH, Pittadaki J. A Comparison of the Availability and Content of Genetic Counseling as Perceived by Hemophilic men and Carriers in the U.S.A., Canada, Scotland and Greece. *Am J Med Genet* 1986; 24: 7-21.
111. Jason JM, McDougal JS, Dixon G, Lawrence DN, Kennedy MS, Hilgartner M, Aledort L, Evatt BL. HTLV-III / LAV Antibody and Immune Status of Household Contacts and Sexual Partners of Persons with Hemophilia. *JAMA* 1986; 255: 2: 212-215.
112. Klimt CR, Knatterud GL, Stamler J, Meier P, and the PARIS II Research Group. Persantine-Aspirin Reinfarction Study. Part II. Secondary Coronary Prevention With Persantine and Aspirin. *JACC* 1986; 7: 2: 251-269.
113. Miller CH, Hilgartner MW, Harris MB, Bussel JB, Aledort LM. Concurrence of von Willebrand's Disease and Hemophilia A: Implications for Carrier Detection and Relevance. *Am J Med Genet* 1986; 24: 83-94.
114. Fruchtman S, Aledort LM. Disseminated Intravascular Coagulation. *JACC* 1986; 8: 6: 159B-167B.
115. O'Grady JG, Langley PG, Isola LM, Aledort LM, Williams R. Coagulopathy of Fulminant Hepatic Failure. *Sem Liver Dis* 1986; 6: 2: 159-163.
116. Driscoll MC, Miller CH, Goldberg JD, Aledort LM, Hoyer, LW, Golbus, MS. Recombination Between Factor VIII: C Gene and St14 Locus. *Lancet (letter)* 1986; 2: 279.
- 116A. Miller CH, Hilgartner MW, Aledort LM. Reproductive Choices in Hemophilic Men and Carriers. *Am J Med Genet* 1987; 26: 591-598.
117. Kerr LD, Spiera H, Aledort LN (sic). Acute disseminated intravascular coagulation as a complication of systemic lupus erythematosus. *NYS J Med* 1987; 87: 181-183.
118. Aledort LM. Factor VIII/ von Willebrand Factor Replacement Therapy. *Ann NY Acad Sci* 1987; 509: 49-52.
119. Perkins HA, Cordell R, Bueno C, Shiota J, Hitchcock B. Progressive decrease in proportion of blood donors with antibody to HIV. *Transfusion* 1987; 27: 502.
120. Miller CH, Aledort LM. Discriminant analysis for probability of hemophilia A carriership. *Blood (editorial)* 1985; 69: 704-705.
121. Carnelli V, Gomperts ED, Friedman A, Aledort L, Hilgartner M, Dietrich S, Fedor EJ. Assessment for evidence of a Non A-Non B hepatitis in patients given n-heptane-suspended heat-treated clotting factor concentrates. *Thromb Res* 1987; 46: 827-834.
122. Niland-Weiss J, Azen SP, Odom-Maryon T, Lui F, Hagerty C, and The Transfusion Safety Study Group. A Microcomputer-Based Distributed Data Management System for a Large Cooperative Study of Transfusion Associated Acquired Immunodeficiency Syndrome. *Comp Biomed Res* 1987; 20: 225-243.
123. Wallace EZ, Aledort LM, Levere R, Mushlin AI. A response to the recommendations of the New York State Commission on Graduate Medical Education concerning teaching in ambulatory care settings. *NYS J Med* 1987; 87: 11: 613-614.

124. Bianchi L, Desmet VJ, Popper H, Scheuer PJ, Aledort LM, Berk PD. Histologic Patterns of Liver Disease in Hemophiliacs, with Special Reference to Morphologic Characteristics of Non-A, Non-B Hepatitis. *Semin Liver Dis* 1987; 7: 3: 203-209.
125. Fletcher MA, Ashman MR, Baron GC. The Use of Whole Blood Methods in Assessment of Immune Parameters in Immuno-Deficiency States. *Diagn Clin Immunol* 1987; 5: 69-81.
126. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J, and the Hemophilia Study Group. The Natural History of Factor VIII:C Inhibitors in Patients With Hemophilia A: A National Cooperative Study. II. Observations on the Initial Development of Factor VIII:C Inhibitors. *Blood* 1988; 71: 2: 344-348.
127. Driscoll MC, Dispenzieri A, Tobias E, Miller CH, Aledort LM. A Second BamHI DNA Polymorphism and Haplotype Association in the Factor IX Gene. *Blood* 1988; 72: 1: 61-65.
128. Wallace EZ, Aledort LM, Levere R, Mushlin AI. Teaching in Ambulatory Care Settings. *NYS J Med* (reply) 1988; 88: 155-156.
129. Aledort LM. Blood Products and Immune Changes: Impacts Without HIV Infection. *Semin Hematol* 1988; 25: 2(suppl): 14-24.
130. Aledort LM, Lipton RA, Hilgartner M. A Consortium for Purchase of Blood Products Directed by Physicians. *Ann Intern Med* 1988; 108: 5: 754-756.
131. Aledort LM, Hilgartner M, Lipton RA. Hemophilia - a treatment in crisis. *N Engl J Med* 1988; 319: 15: 1017.
132. Bussel JB, Pham LC, Aledort L, Nachman R. Maintenance Treatment of Adults With Chronic Refractory Immune Thrombocytopenic Purpura Using Repeated Intravenous Infusions of Gammaglobulin. *Blood* 1988; 72: 1: 121-127.
133. Aledort LM. Cryoprecipitate revisited. *Transfusion* (editorial) 1988; 28: 4: 295-296.
134. Gjerset G, Vyas GN, Bhat R, Operskalski EA, and the Transfusion Safety Study Group. Phenotypes for Group-Specific Component Among Patients Exposed to Human Immunodeficiency Virus by Transfusions. *J Infect Dis* 1988; 157: 3: 609-610.
135. Govindarajan S, Edwards VM, Stuart ML, Operskalski EA, Mosley JW, and the Transfusion Safety Study Group. Influence of Human Immunodeficiency Virus Infection on Expression of Chronic Hepatitis B and D Virus Infections. *Viral Hep Liv Dis* 1988; 201-204.
136. Kaplan J, Sarnaik I, Lusher J, and the Transfusion Safety Study Group. Increase in Leu 2⁺ Leu 7⁺ Lymphocytes in HIV 1-Seropositive Patients with Hemophilia Repeatedly Treated With Clotting Factor Concentrates. *Clin Immunol Immunopath* 1988; 46: 337-341.
137. Aledort LM. Risks Associated With Homologous Blood Transfusion. *J Cardiothor Anesth* 1988; 2: 6(suppl): 2-6.
138. Bishop PC, Boone D, Parker JW. Immunophenotypes by Flow Cytometry: A Longitudinal Study in Healthy Individuals. *Diagn Clin Immunol* 1988; 5: 232-240.
139. Brown NA, Kovacs A, Lui CR, Hur C, Zaia JA, Mosley JW. Prevalence of antibody to Human Herpesvirus 6 among blood donors infected with HIV. *Lancet* 1988; 2: 1146.
- 139A. Lawrence DN, Jason JM, Holman RC, Heine P, Evatt BL, and the Hemophilia Study Group.

- Sex Practices Correlates of Human Immunodeficiency Virus Transmission and Acquired Immunodeficiency Syndrome Incidence in Heterosexual Partners and Offspring of U.S. Heterosexual Men. *Am J Hematol* 1989; 30: 68-76.
140. Norman GL, Barker SS, Rasheed S, and the Transfusion Safety Study Group. Immunoblot Reactivity of a Non-HIV Protein With Human Sera. *J Clin Lab Anal* 1989; 3: 148-151.
 141. Uehlinger J, Rose E, Aledort LM. Successful treatment of an acquired von Willebrand factor antibody by extracorporeal immunoadsorption. *N Engl J Med* 1989; 320: 4: 254-255.
 142. Aledort LM. New Approaches to Management of Bleeding Disorders. *Hosp Prac* 1989; 24: 2: 207-226.
 143. Edwards VM, Mosley JW, and the Transfusion Safety Study Group. Reproducibility in Quality Control of Protein (Western) Immunoblot Assay for Antibodies to Human Immunodeficiency Virus. *Am J Clin Pathol* 1989; 91: 1: 75-78.
 144. Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White II GC, Drummond JE, Vaidya K, Mann DL, Eyster ME, Ragni MV, Lederman MM, Cohen AR, Bray GL, Rosenberg PS, Friedman RM, Hilgartner MW, Blattner WA, Kroner B, Gail MH. A prospective study of Human Immunodeficiency Virus Type 1 Infection and the development of AIDS in subjects with Hemophilia. *N Engl J Med* 1989; 321: 17: 1141-1148.
 145. Antman KH, Aledort LM, Yarbrow J, Wilensky G, Wojcik S, Monaco GP, Windham S. Cost-effectiveness and Reimbursement in Patient Care. *Semin Hematol* 1989; 26: 3(suppl): 32-45.
 146. Driscoll MC, Bouhassira E, Aledort LM. A Codon 338 Nonsense Mutation in the Factor IX Gene in Unrelated Hemophilia B Patients: Factor IX³³⁸ New York. *Blood* 1989; 74: 2: 737-742.
 147. Fletcher MA, Azen SP, Adelsberg B, Gierset G, Hassett J, Kaplan J, Niland JC, Odom-Maryon T, Parker JW, Stites DP, Mosley JW, and the Transfusion Safety Study Group. Immunophenotyping in a Multicenter Study: The Transfusion Safety Study Experience. *Clin Immunol Immunopath* 1989; 52: 38-47.
 148. Aledort LM, Essig B. AIDS Laws - Impractical Solutions to Practical Problems. *Hosp Prac* 1989 July; 11-12.
 149. McClure E, Gaynor S, Veiga-Benach A, O'Neil D, and the Transfusion Safety Study Group. Notification of Recipients of Human Immunodeficiency Virus (HIV) Antibody Positive Transfusions. *Nursing* 1989; January: 10.
 150. Mosley JW, Nowicki M, Kleinman SH, Dietrich SL, and the Transfusion Safety Study Group. Reactivation of Hepatitis B. *Lancet* 1989; 1: 1083-1084.
 151. Kleinman SH, Niland JC, Azen SP, Operskalski EA, Barbosa LH, Chernoff AI, Edwards VM, Lenos BA, Marshall GJ, Nemo GJ, Norman GL, Perkins NH, Pindyck J, Pitlick F, Rasheed S, Shriver K, Toy P, Tomasulo PA, Waldman A, Mosley JW, and the Transfusion Safety Study Group. Prevalence of antibodies to Human Immunodeficiency Virus Type 1 among blood donors prior to screening. *Transfusion* 1989; 29: 7: 572-580.
 152. Operskalski EA, Schiff ER, Kleinman SH, Busch M, Taylor PE, Parks WP, Lee H, Tomasulo PA, Tomasulo PA, Donegan E, Stuart M, Hollingsworth CG, Nemo GJ, Mosley JW, and the Transfusion Safety Study Group. Epidemiologic background of blood donors with antibody to human T-cell lymphotropic virus. *Transfusion* 1989; 29: 8: 746-748.

153. Lang DJ, Kovacs AAS, Zaia JA, Doelkin G, Niland JC, Aledort L, Azen SP, Fletcher MA, Gauderman J, Gjerset GJ, Lusher J, Operskalski EA, Parker JW, Pegelow C, Vyas GN, Mosley JW, and the Transfusion Safety Study Group. Seroepidemiologic Studies of Cytomegalovirus and Epstein-Barr Virus Infections in Relation to Human Immunodeficiency Virus Type 1 Infection in Selected Recipient Populations. *J Acq Imm Def Syndr* 1989; 2: 540-549.
154. Uehlinger J, Aledort LM. Blood-Product Usage in Cardiac Surgery. *J Cardiothor Anesth* 1989; 3: 6: 776-784.
155. Brettler DB, Forsberg AD, Levine PH, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H, and the Cooperating Investigators. The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients With Inhibitor Antibodies to Factor VIII. *Arch Intern Med* 1989; 149: 1381-1385.
156. Jason J, Ou CY, Moore JL, Lawrence DN, Schochetman G, Evatt BL. Prevalence of Human Immunodeficiency Virus Type 1 DNAP in Hemophilic Men and Their Sex Partners. *J Infect Dis* 1989; 160: 789-794.
157. Rose E, Forster A, Aledort LM. Correction of prolonged bleeding time in von Willebrand's disease with Humate-P. *Transfusion* 1990; 30: 4: 381.
158. Parker JW, Adelsberg B, Boone D, and the Transfusion Safety Study Group. Leukocyte Immunophenotyping of Recipients of Blood and Blood Products. A Multisite Flow Cytometry study: Approach to Organization, Standardization, Quality Control, and Date Management. *Clin Immunol Immunopath* 1990; 55: 187-220.
159. Busch MP, Donegan E, Stuart M, Mosley JW, and the Transfusion Safety Study Group: Donor HIV-1 p24 Antigenemia and Course of Infection in Recipients. *Lancet* 1990; 1: 1342.
160. Hilgartner M, Aledort L, Andes A, Gill J, and the members of the FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. *Transfusion* 1990; 30: 626-630.
- 160A. Lipton RA, Aledort LM, Hilgartner M. The physician-directed blood product purchasing consortium during a worldwide shortage of factor VIII concentrate. *Transfusion* 1990; 30: 6: 573.
161. Uehlinger J, Button GR, McCarthy J, Forster A, Watt R, Aledort LM. Immunoabsorption for coagulation factor inhibitors. *Transfusion* 1991; 31: 3: 265-269.
162. Donegan E, Busch MP, Galleshaw JA, Shaw GM, Mosley JW, and the Transfusion Safety Study Group. Transfusion of Blood Components from a Donor with Human T-Lymphotropic Virus Type II (HTLV-II) Infection. *Ann Intern Med* 1990; 113: 555-556.
163. Dietrich SL, Mosley JW, Lusher JM, Hilgartner MW, Operskalski EA, Habel L, Aledort LM, Gjerset GF, Koerper MA, Lewis BH, Pegelow CH, and the Transfusion Safety Study Group. Transmission of Human Immunodeficiency Virus Type 1 by Dry-Heated Clotting Factor Concentrates. *Vox Sang* 1990; 59: 129-135.
164. Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, Faucett C, Fletcher MA, Hagerty C, Kleinman SH, Operskalski EA, Perkins H, Pindyck J, Schiff ER, Stites D, Tomasulo PA, Mosely JW, and the Transfusion Safety Study Group. Infection with Human Immunodeficiency Virus Type 1 (HIV-1) among Recipients of Antibody-Positive Blood Donations. *Ann Intern Med* 1990; 113: 733-739.
165. Busch MP, Taylor PE, Lenes BA, Kleinman SH, Stuart M, Stevens CE, Tomasulo PA, Allain JP,

- Hollingsworth CG, Mosley JW, and the Transfusion Safety Study Group. Screening of selected male blood donors for p24 antigen of Human Immunodeficiency Virus Type 1. *N Engl J Med* 1990; 323: 19: 1308-1312.
166. Alter HJ, Epstein JS, Swenson SG, VanRaden MJ, Ward JW, Kaslow RA, Menitove JE, Klein HG, Sandler SG, Sayers MH, Hewlett IK, Chernoff AI, and the HIV-Antigen Study Group. Prevalence of Human Immunodeficiency Virus Type 1 p24 antigen in U.S. blood donors - an assessment of the efficacy of testing in donor screening. *N Engl J Med* 1990; 323: 19: 1312-1317.
 167. Aly AM, Aledort LM, Lee TD, Hoyer LW. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. *Br J Haematol* 1990; 76: 238-241.
 168. Miller K, Donegan E, Curran P, Shelley TJ, and the Transfusion Safety Study Group. Effects of counselling on knowledge about HIV-1 among transfusion recipients and their partners. *AIDS Care* 1990; 2: 2: 155-162.
 169. Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ, Kasper CK, Kernoff PBA, Levine PH, Lusher JM, Mannucci PM, Scharrer I, MacKenzie MA, Pancham N, Kuo HS, Allred RU, and the Recombinant Factor VIII Study Group. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of Hemophilia A. *N Engl J Med* 1990; 323: 26: 1800-1805.
 170. Uehlinger J, Button GR, McCarthy J, Forster A, Watt R, Aledort LM. Immunoabsorption for coagulation factor inhibitors. *Transfusion* 1991; 31: 3: 265-269.
 171. Rose EH, Aledort LM. Nasal Spray Desmopressin (DDAVP) for Mild Hemophilia A and von Willebrand Disease. *Ann Intern Med* 1991; 114: 7: 563-568.
 172. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Analysis of Efficacy, Toxicity, and Mechanism of Effect. *Blood* 1991; 77: 9: 1884-1893.
 173. Aledort LM. Von Willebrand's Disease - A Therapeutic Challenge. *Biomed Prog* 1991; 4: 3:43-47.
 174. Aledort LM. Treatment of von Willebrand's Disease. *Mayo Clin Proc* 1991; 66: 841-846.
 175. Weiss HM, Simon R, Levi J, Forster A, Hubbard M, Aledort L. Compliance in a Comprehensive Hemophilia Center and Its Implications for Home Care. *Fam Syst Med* 1991; 9: 2: 111-120.
 176. Aledort LM. A Safe Approach to Treatment of Factor IX-Deficient Patients. Introduction and Overview of Treatment. *Semin Hematol* 1991; 28: 3(suppl 6): 1-2.
 177. Arkin S, Rose E, Forster A, Aledort LM for the rFactor VIII Clinical Trial Group. Clinical Efficacy of Recombinant Factor VIII. *Semin Hematol* 1991; 28: 2(suppl 1): 47-51.
 178. Aledort LM. Factor Concentrates in Hemophilia - Is Purer Better? *Biomed Prog* 1991; 4: 49-50.
 179. Aledort LM: Das von Willebrand-Syndrom: eine therapeutische Herausforderung. *Die gelben Hefte* 1991; 31: 123-130.
 180. Lusher JM, Operskalski EA, Aledort LM, Dietrich SL, Gjerset GF, Hilgartner MW, Koerper MA, Pegelow CH, Lee H, Mosley JW. Risk of Human Immunodeficiency Virus Type 1 Infection Among Sexual and Nonsexual Household Contacts of Persons With Congenital Clotting Disorders. *Pediatrics* 1991; 88: 2: 242-249.

181. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual Co-Transmission of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV). *Ann Intern Med* 1991; 115: 10: 764-768.
182. Aledort LM, Hilgartner MW, Pike MC, Gjerset GF, Moerper MA, Lian EYC, Lusher JM, Mosley JW (on behalf of the Transfusion Safety Study Group). Variability in serial CD4 counts and relation to progression of HIV-1 infection to AIDS in haemophilic patients. *Brit Med J* 1992; 304: 212-216.
183. Aledort L. Discussion Moderator: Dr. L. Aledort: Factor VIII inhibitors in a haemophilic population treated with low and high purity FVIII concentrates. *Blood Coag Fibrin* 1991; 2: 1: 25-30.
184. Parks WP, Lenes BA, Tomasulo PA, Schiff ER, Parks ES, Shaw GM, Lee H, Yan HQ, Lai S, Hollingsworth CG, Nemo GJ, Mosley JW, and the Transfusion Safety Study Group. Human T-Cell Lymphotropic Virus Infection among Blood Donors in South Florida. *J Acq Imm Def Synd* 1991; 4: 1: 89-96.
185. Odom-Maryon T, Langholz B, Niland J, Azen S. Generalization of Normal Discriminant Analysis using Fourier Series Density Estimators. *Stats Med* 1991; 10: 473-485.
186. Donegan E, Lenes BA, Tomasulo PA, Mosely JW, and the Transfusion Safety Study Group. Transmission of HIV-1 by component type and duration of shelf storage before transfusion. *Transfusion* 1990; 30: 9: 851-852.
187. Busch MP, Young MO, Samson SS, Ward J, Perkins HA, and the Transfusion Safety Study Group. Risk of Human Immunodeficiency Virus Transmission by Blood Transfusions prior to HIV Antibody Screening: Estimate of the Number and Proportion of Recipients Infected by Year of Transfusion in the San Francisco Bay Area. *Transfusion* 1991; 31: 4-11.
188. Rabkin CS, Hilgartner MW, Hedberg KW, Aledort LM, Hatzakis A, Eichinger S, Eyster ME, White II GC, Kessler CM, Lederman MM, de Moerloose P, Bray GL, Cohen AR, Andes WA, Manco-Johnson M, Schramm W, Kroner BL, Blattner WA, Goedert JJ. Incidence of Lymphomas and Other Cancers in HIV-Infected and HIV-Uninfected Patients With Hemophilia. *JAMA* 1992; 267: 8: 1090-1094.
189. Mannucci PM, Schimpf K, Abe T, Aledort LM, Anderle K, Brettler DB, Hilgartner MW, Kernoff PBA, Kunschak M, McMillan CW, Preston FE, Rivard GE, and the International Investigator Group. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. *Transfusion* 1992; 32: 2: 134-138.
190. Dublin S, Rosenberg PS, Goedert JJ. Patterns and predictors of high-risk sexual behavior in female partners of HIV-infected men with hemophilia. *AIDS* 1992; 6: 475-482.
191. Growe GH, Poon MC, Scarth I. International Symposium on Recombinant Factor VIII: Report of the Proceedings. *Trans Med Rev* 1992; 4: 2: 137-145.
192. Fletcher MA, Mosley JW, Hassett J, Gjerset GF, Kaplan J, Parker JW, Donegan E, Lusher JM, Lee H, and the Transfusion Safety Study Group. Effect of Age on Human Immunodeficiency Virus Type 1-Induced Changes in Lymphocyte Populations Among Persons With Congenital Clotting Disorders. *Blood* 1992; 80: 3: 831-840.
193. Aledort LM. Prophylaxis: the next haemophilia treatment. *J Intern Med* (editorial) 1992; 232: 1-2.

194. Aledort LM. A Perspective on Inhibitor Development and Factor VIII Concentrates. *Amer Red Cross* 1992; 1-8.
195. Aledort LM. Arthropathy and Substitution Therapy. *Haemostasis* 1992; 22: 245-246.
196. Aledort LM, Operskalski EA, Dietrich SL, Koerper MA, Gjerset GF, Lusher JM, Kian ECY, Mosley JW, and the Transfusion Safety Study Group. Low CD4⁺ counts in a study of transfusion safety. *N Engl J Med* 1993; 328: 6: 441-442.
197. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, and the Kogenate Previously Untreated Patient Study Group. Recombinant Factor VIII for the treatment of previously untreated patients with Hemophilia A. *N Engl J Med* 1993; 328: 7: 453-459.
198. Seremetis SV, Aledort LM. Congenital Bleeding Disorders: Rational Treatment Options. *Drugs* 1993; 45: 4: 1-7.
199. Eyster ME, Rabkin CS, Hilgartner MW, Aledort LM, Ragni MV, Sprandio J, White GC, Eichinger S, de Moerloose P, Andes WA, Cohen AR, Manco-Johnson M, Bray GL, Schramm W, Hatzakis A, Lederman MM, Kessler CM, Goedert JJ. Human Immunodeficiency Virus-Related Conditions in Children and Adults With Hemophilia: Rates, Relationship to CD4 Counts, and Predictive Value. *Blood* 1993; 81: 3: 828-834.
200. Nowicki MJ, Mosley JW, Koerper MA, Aledort LM, Lusher JM, Hilgartner MW for the Transfusion Safety Group. Passive antibody to hepatitis A virus in US haemophiliacs. *Lancet* 1993; 341: 562.
201. Bray GL, Kroner BL, Arkin S, Aledort LM, Hilgartner MW, Eyster ME, Ragni MV, Goedert JJ. Loss of High-Responder Inhibitors in Patients With Severe Hemophilia A and Human Immunodeficiency Virus Type 1 Infection. *Am J Hematol* 1993; 42: 375-379.
202. Ragni MV, Belle SH, Jaffe RA, Duerstein SL, Bass DC, McMillan CW, Lovrien EW, Aledort LM, Kisker CT, Stabler SP, Hoots WK, Hilgartner MW, Cox-Gill J, Buchanan GR, Sanders NL, Brettler DB, Barron LE, Goldsmith JC, Ewenstein B, Smith KJ, Green D, Addiego JE, Kingsley LA. Acquired Immunodeficiency Syndrome-Associated Non-Hodgkin's Lymphomas and other Malignancies in Patients With Hemophilia. *Blood* 1993; 81: 7: 1889-1897.
203. Aledort LM. World Registry of Factor VIII Inhibitor Patients: Why? *Semin Hematol* 1993; 30: 2: 1(suppl): 7-9.
204. Adams M, Lee TH, Busch MP, Heitman J, Marshall GJ, Gjerset GF, Mosley JW, and the Transfusion Safety Study Group. Rapid freezing of whole blood or buffy coat samples for polymerase chain reaction and cell culture analysis: application to detection of human immunodeficiency virus in blood donor and recipient repositories. *Transfusion* 1993; 33: 6: 504-508.
205. Aledort LM. Prophylaxis: A Future Therapy for Hemophilia, Athens Greece. *Int Cong World Fed Hemophil* 1993; 30: 3: 2.
206. Aledort LM. Consequences of Chronic Hepatitis C: A Review Article for the Hematologist. *Am J Hematol* 1993; 44: 29-37.
207. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ for the Multicenter Hemophilia Cohort Study. Natural History of Hepatitis C Virus Infection in Multitransfused Hemophiliacs: Effect of Coinfection with Human Immunodeficiency Virus. *J Acq Imm Def Synd* 1993; 6: 602-610.

208. Seremetis SV, Aledort LM, Bergman GE, Bona R, Bray G, Brettler D, Eyster ME, Kessler C, Lau TS, Lusher J, Rickles F. Three-year randomized study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV seropositive haemophiliacs: effects on immune status. *Lancet* 1993; 342: 700-703.
209. Aledort LM. Introduction: Replacement Therapy for Hemophilia: Impact on the Immune System. *Semin Hematol* 1993; 30: 4: 5(suppl): 1.
210. Rabkin CS, Hatzakis A, Griffiths PD, Pillay D, Ragni MV, Hilgartner MW, Goedert JJ, and the National Cancer Institute Multicenter Hemophilia Cohort Study Group. Cytomegalovirus Infection and Risk of AIDS in Human Immunodeficiency Virus-Infected Hemophilia Patients. *J Inf Dis* 1993; 168: 1260-1263.
211. Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ for the Multicenter Hemophilia Cohort Study. HIV-1 Infection Incidence Among Persons with Hemophilia in the United States and Western Europe. *J Acq Imm Def Synd* 1994; 7: 279-286.
212. Aledort LM, Hoyer LW, Lusher JM, Nilsson IM. Recent developments in the study of inhibitors to factor VIII therapy. *Mt Sinai Sch Med* 1994; 4: 1-24.
213. Eickhoff TC, White LJ, Gullen DJ, Addington W, Aledort LM, Fryhofer SA, Jackson EB, Lurie N, Sams BJ, Tooker JP, Winslow CM, Cleaveland CR, Samuelson CO, Berenson RA, Cassel CK, Eisenberg JM, Gullen DJ; et al. Human Immunodeficiency Virus (HIV) Infection. *Ann Intern Med* 1994; 120: 4: 310-319.
214. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White III G, Lee M, and the Recombinate Study Group. A Multicenter Study of Recombinant Factor VIII (Recombinate: Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A. *Blood* 1994; 83: 9: 2428-2435.
215. Mosley JW, Nowicki MJ, Kasper CK, Donegan E, Aledort LM, Hilgartner MW, Operskalski EA, The Transfusion Safety Study Group. Hepatitis A Virus Transmission by Blood Products in the United States. *Vox Sang* 1994; 67: 1(suppl): 24-28.
216. Rosenberg PS, Goedert JJ, Biggar RJ for the Multicenter Hemophilia Cohort Study, and the International Registry of Seroconverters: Effect of age at seroconversion on the natural AIDS incubation distribution. *AIDS* 1994; 8: 803-810.
217. Gjerset GF, Pike MC, Mosley JW, Hassett J, Fletcher MA, Donegan E, Parker JW, Counts RB, Zhou Y, Kasper CK, Operskalski EA, and the Transfusion Safety Study Group. Effect of Low and Intermediate Immunodeficiency Virus Infection in Congenital Clotting Disorders. *Blood* 1994; 84: 5: 1666-1671.
218. Aledort LM, Haschmeyer RH, Pettersson H, and the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. *J Intern Med* 1994; 236: 391-399.
219. Mannucci PM, Brettler DB, Aledort LM, Lusher JM, Abildgaard CF, Schwartz RS, Hurst D, and the Kogenate Study Group. Immune Status of Human Immunodeficiency Virus Seropositive and Seronegative Hemophiliacs Infused for 3.5 Years With Recombinant Factor VIII. *Blood* 1994; 83: 7: 1958-1962.
220. Bray GL, Aledort LM, Lipton R, Hilgartner M, Seremetis S, Cohen AR, Rivard GE, Inwood MJ, Blanchette V, Kessler CM, Lusher JM, Arkel YS, Bauer K. Considerations governing factor IX product choice in hemophilia B. *Transfusion* 1994; 34: 6: 554-555.

221. Aledort L. Inhibitors in Hemophilia Patients: Current Status and Management. *Am J Hematol* 1994; 47: 208-217.
222. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ, and the Multicenter Hemophilia Cohort Study. Increasing Hepatitis C Virus RNA Levels in Hemophiliacs: Relationship to Human Immunodeficiency Virus Infection and Liver Disease. *Blood* 1994; 84: 4: 1020-1023.
223. Ehmann WC, Eyster ME, Wilson SE, Andes WA, Goedert JJ, and the Multicenter Hemophilia Cohort Study. Relationship of CD4 Lymphocyte Counts to Survival in a Cohort of Hemophiliacs Infected With HIV. *J Acq Imm Def Synd* 1994; 7: 1095-1098.
224. Rosenberg PS, Goedert JJ, Biggar RJ for the Multicenter Hemophilia Cohort Study, and the International Registry of Seroconverters. Effect of Age at Seroconversion on the Natural AIDS Incubation Distribution. *AIDS* 1994; 8: 803-810.
225. Goedert JJ, Cohen AR, Kessler CM, Eichinger S, Seremetis SV, Rabkin CS, Yellin FJ, Rosenberg PS, Aledort LM, for the Multicenter Hemophilia Cohort Study. Risks of Immunodeficiency, AIDS, and Death Related to Purity of Factor VIII Concentrate. *Lancet* 1994; 344: 791-792.
226. Cagnoni PJ, Aledort L. Gastrointestinal Bleeding in Hemophilia as a Complication of the Use of Over the Counter Non-Steroidal Anti-Inflammatory Drugs. *Ann Intern Med* 1994; 336-337.
227. Gaynor S, Aledort L, Hilgartner M, Lipton R, Saidi P, Strazzabosco J, Pratok P. Haemophilia treatment centres: old and new challenges. *Lancet* 1995; 345: 653.
228. Poon MC, Aledort LM, Anderle K, Kunschak M, Morfini M, and the Factor IX Study Group. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. *Transfusion* 1995; 35: 319-323.
229. Koblin BA, Aledort L, Hilgartner M, Lipton R, Goldberg I, Gaynor S, Feeley M, Forster A, Taylor P, Stevens CE. A study of hepatitis A virus infection among hemophilia patients in New York City. *Transfusion* 1995; 35: 4: 362-363.
230. Shapiro A, Abe T, Aledort LM, Anderle K, Hilgartner MW, Kunschak M, Preston FE, Rivard GE, Schimpf K, and the International Factor Safety Study Group. Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. *Transfusion* 1995; 35: 204-208.
231. Kroner BL, Goedert JJ, Blattner WA, Wilson SE, Carrington MN, Mann DL for the Multicenter Hemophilia Cohort, and Hemophilia Growth and Development Studies. Concordance of human leukocyte antigen haplotype-sharing, CD4 decline and AIDS in hemophilic siblings. *AIDS* 1995; 9: 275-280.
232. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia Home Treatment. *Int J Tech Assess Hth Care* 1995; 11: 2: 327-344.
233. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. *Transfusion* 1995; 35: 5: 427-430.
234. Aledort LM. Some Aspects on the Management of Hemophilia. *Thromb Hemophil* 1995; 74: 1: 440-443.
235. Arkin S, Aledort LM. Kogenate: A recombinant technology-derived human antihemophilic factor (FVIII) concentrate. *Drugs of Today* 1995; 31: 3: 173-183.

236. Lederman MM, Jackson JB, Kroner BL, White III GC, Eyster ME, Aledort LM, Hilgartner MW, Kessler CM, Cohen AR, Kiger KP, Goedert JJ. Human Immunodeficiency Virus (HIV) Type 1 Infection Status and In Vitro Susceptibility to HIV Infection among High-Risk HIV-1-Seronegative Hemophiliacs. *J Infect Dis* 1995; 172: 228-231.
237. Aledort LM. Medical necessity - a threat to treatment of chronic disease. *Transfusion* 1995; 35: 712.
238. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A Prospective Study of Treatment of Acquired (Autoimmune) Factor VIII Inhibitors With High-Dose Intravenous Gammaglobulin. *Blood* 1995; 86: 2: 797-804.
239. Brown LK, Schultz JR, Gragg RA, for the Hemophilia Behavioral Intervention Evaluation Project. HIV-Infected Adolescents With Hemophilia: Adaptation and Coping. *Pediatrics* 1995; 96: 3: 459-463.
240. Ehmann WC, Eyster ME, Aledort LM, Goedert JJ. Causes of death in haemophilia. *Nature* 1995; 378: 124.
241. Aledort LM. Inhibitors to Coagulation: Can We Afford Immune Tolerance Induction Regimens? *Vox Sang* 1996; 70: 1(suppl): 77-78.
242. Kessler CM, Aledort LM. The Economics of Immune Tolerance and Treatment of Hemophiliacs with Inhibitors. *Vox Sang* 1996; 70: 1(suppl): 74-76.
243. Aledort LM, Mohandas K. Transfusion Requirements in Patients With Malignancy. *Semin Hematol* 1996; 33: 1: 1(suppl): 6-9.
244. Aledort LM. Hemophilia: Yesterday, Today, and Tomorrow. *Mt Sinai J Med* 1996; 63: 3&4: 225-235.
245. Aledort LM, Bohn RL. Prophylaxis and constant infusion for hemophilia: can we afford it? *Blood Coag Fibrin* 1996; 7: 1(suppl).
246. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods. *Am Soc Hematol* 1996; 88: 1: 3-40.
247. O'Brien TR, Blattner WA, Waters D, Eyster ME, Hilgartner MW, Cohen AR, Luban N, Hatzakis A, Aledort LM, Rosenberg PS, Miley WJ, Kroner BI, Goedert JJ for the Multicenter Hemophilia Cohort Study. Serum HIV-1 RNA Levels and Time to Development of AIDS in the Multicenter Hemophilia Cohort Study. *JAMA* 1996; 276: 2: 105-110.
248. Gilbert MS, Aledort LM, Seremetis S, Needleman B, Oloumi G, Forster A. Long Term Evaluation of Septic Arthritis in Hemophilic Patients. *Clin Orthopaed* 1996; 328: 54-59.
249. Ragni MV, Belle SH, Jaffe R, Locker J, Duerstein SL, Bass DC, Addiego JE, Aledort LM, Barron LE, Brettler DB, Buchanan GR, Gill JC, Ewenstein BM, Green D, Hilgartner MW, Hoots WK, Kisker CT, Lovrien EW, Rutherford CJ, Sanders NL, Smith KJ, Stabler SP, Swindells S, White III GC, Kingsley LA for the Hemophilia Malignancy Study Group. AIDS-Associated Non-Hodgkin's Lymphomas as Primary and Secondary AIDS Diagnoses in Hemophiliacs. *J Acq Imm Def Synd Human Retroviral* 1996; 13: 78-86.
250. The American Society of Hematology ITP Practice Guideline Panel: Clinical Guidelines - Diagnosis and Treatment of Idiopathic Thrombocytopenic Purpura: Recommendations of the

- American Society of Hematology. *Ann Intern Med* 1997; 126: 319-326.
251. Schwartz JD, Aledort LM, Seremetis SV. Liver failure and mortality in HIV-positive haemophiliacs: fourteen-year experience and literature review. *Haemophil* 1997; 3: 24-30.
 252. Aledort LM, Forster A, Maksoud J, Isola L. BPL factor XI concentrate: clinical experience in the USA. *Haemophil* 1997; 3: 59-62.
 253. Scaradavou A, Woo B, Woloski BMR, Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB. Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272 Patients. *Blood* 1997; 89: 8: 2689-2700.
 254. Seremetis SV, Aledort LM. Desmopressin Nasal Spray for Hemophilia A and Type 1 von Willebrand Disease. *Ann Intern Med* 1997; 126: 9: 744-745.
 255. Aledort LM. Global hemophilia care. *Int Monit Hemophil* 1997; 5: 1: 3-5.
 256. Aledort LM. von Willebrand Disease: From the Bedside to Therapy. *Thromb Haemost* 1997; 78: 1: 562-565.
 257. Gail MH, Tan WY, Pee D, Goedert JJ for the Multicenter Hemophilia Cohort Study. Survival After AIDS Diagnosis in a Cohort of Hemophilia Patients. *J Acq Imm Def Synd Human Retroviral* 1997; 15: 363-369.
 258. Ehmann WC, Rabkin CS, Eyster ME, Goedert JJ for the Multicenter Hemophilia Cohort Study. Thrombocytopenia in HIV-Infected and Uninfected Hemophiliacs. *Am J Hematol* 1997; 54: 296-300.
 259. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study, O'Brien SJ. Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression. *Science* 1997; 277: 959-965.
 260. Goedert JJ, Erdman DD, Konkle BA, Török TJ, Lederman M, Kleinert D, Mandalaki T, Kessler CM, Anderson LJ, Luban NLC for the Multicenter Hemophilia Cohort Study. Parvovirus B19 Quiescence During the Course of Human Immunodeficiency Virus Infection in Persons With Hemophilia. *Am J Hematol* 1997; 56: 1-4.
 261. Aledort LM, Hay C. Porcine Factor VIII: Its Role in the Management of Congenital and Acquired Inhibitors. *Haemophil* 1997; 3: 3.
 262. Kavakli K, Aledort LM. Circumcision and haemophilia: a perspective. *Haemophil* 1998; 4: 1-3.
 263. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs (letter to the editor). *Haemophil* 1998; 4: 66-68.
 264. Aledort L, Bohn R, Bolton-Maggs P, Economides D, Kadir R, Lee C, Lethagen S, Ljung R, Mannucci P, Miller R, Teitel J. Meeting report: A meeting held in London, 12-13 January 1998, to discuss bleeding disorders in women. *Haemophil* 1998; 4: 145-154.
 265. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic Use of Factor VIII: an Economic Evaluation. *Thromb Haemost* 1998; 79: 932-937.
 266. Aledort LM. Unsolved problems in haemophilia. *Haemophil* 1998; 4: 4: 341-345.

267. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors. *Thromb Haemost* 1998; 80: 912-918.
268. Aledort LM. Transfusion-induced hepatitis C and hepatocellular carcinoma. *Int Mon Hemophilia* 1998; 6: 2: 26.
269. Lusher LM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM and the rFIIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous hemorrhages in persons with haemophilia A and B, with and without inhibitors. *Haemophil* 1998; 4: 790-798.
270. Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D and the Kogenate® Study Group. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. *Haemophil* 1999; 5: 9-16.
271. Aledort LM. Bleeding - A Challenge to the Intensivist. *Crit Care & Shock (Indonesian Soc. of Critical Care Medicine)* 1999; 2: 1: 1-2.
272. White GC II, Courter S, Bray GL, Lee M, Gomperts ED and The Recombinate Previously Treated Patient Study Group. A Multicenter Study of Recombinant Factor VIII (Recombine™) in Previously Treated Patients with Hemophilia A. *Thromb Haemost* 1997; 2: 4: 660-667.
273. Aledort LM, Miners A, Bohn R, Borrero P, Goudemand J, Hoots K, Kavakli K, Lee C, Roberts J, Schramm W, Szucs T, Wasserman J. Meeting report: Economic aspects of haemophilia care. *Haemophilia* 1999; 5: 216-219.
274. Engels EA, Rosenberg PS, O'Brien TR, and Goedert JJ, for the Multicenter Hemophilia Cohort Study. Plasma HIV Viral Load in Patients with Hemophilia and Late-Stage HIV Disease: A Measure of Current Immune Suppression. *Ann Intern Med* 1999; 131: 256-264.
275. Aledort LM and the Baxter Previously Untreated Patient Study Group. Immune tolerance induction in hemophiliacs: Can we afford it? Is it worth it? *Transfusion* 1999; 39: 1034-1035.
276. Aledort LM, Colowick A, Hoots WK, Dunst IP. Economic aspects of haemophilia care in the United States. *Haemophilia* 1999; 5: 282-285.
277. Pollman H, Aledort L. Albumin-Free Formulated Recombinant Factor VIII Preparations - How Big a Step Forward? *Thromb Haemost* 1999; 82: 4: 1370-1371.
278. Aledort LM. Prophylaxis: for whom, when at what cost to patient and society? *Int Monitor on Hemophilia* 1999; 7: 2: 20-21.
279. Brown SA, Aledort LM, Lee CA, Barrowcliffe TW, Berntorp E, Ewenstein BM, Kessler CM, Ludlam CA, Mannucci PM, Mauser-Bunschoten EP, Miller R, Minor PD, Penner JA, Petrini P, Rossi F, and Srivastava A. Meeting Report: Issues in making a therapeutic choice: recombinant and/or human-derived products. *Haemophilia* 2000; 6: 2: 125-129.
280. Aledort LM. Immune tolerance in hemophilia and inhibitors: a cost analysis. (Letter to the Editor). *Transfusion* 2000; 40: 495-496.
281. Aledort LM. Recombinant VIIa Is a Pan-hemostatic Agent? *Thromb Haemost* 2000; 83: 637-638.

282. Rothschild C, Gill J, Scharrer I, Bray, G and the Recombinate PUP Study Group. Transient Inhibitors in the Recombinate Pup Study. *Thromb Haemost* 2000; 84: 145-146.
283. Aledort LM. Immune Tolerance Induction: Is it cost-effective? We know too little. *Seminars in Thrombosis and Hemostasis* 2000; 26: 2: 189-193.
284. Goodeve AC, Williams I, Bray GL, Peake IR for the Recombinate™ PUP Study Group. Relationship between Factor VIII Mutation Type and Inhibitor Development in a Cohort of Previously Untreated Patients Treated with Recombinant Factor VIII (Recombine™). *Thromb Haemost* 2000; 83: 844-848.
285. Brown LK, Schultz JR, Parsons JT, Butler RB, Forsberg AD, Kocik SM, King G, Manco-Johnson M, Aledort L, for the Adolescent Hemophilia Behavioral Intervention Evaluation Project Study Group: Sexual Behavior Change Among Human Immunodeficiency Virus-Infected Adolescents With Hemophilia. *Pediatrics* 2000; 106: 2: 1-6.
286. Aledort LM. rVIIa - its Thrombogenicity (Letter to the Editor). *Thromb Haemost* 2000; 84: 3: 522-523.
287. Aledort LM. Unexpected bleeding disorders: identification, diagnosis and management (Meeting Report). *Haemophilia* 2000; 6: 592-594.
288. Kadir RA, Aledort LM. Obstetrical and gynaecological bleeding: a common presenting symptom. *Clin and Laboratory Haematol* 2000; 22 (Suppl. 1): 12-16.
289. Aledort LM. The economics of hemophilia care: its great disparity. *Intl Monitor on Hemophilia* 2000; 8: 2: 16-17.
290. Aledort LM. Rebuttal to Massive Skin Necrosis Associated to the Prothrombin Gene G20210A Mutation. *Thromb Haemost* 2001; 85: 2: 374.
291. Aledort LM. Meeting Report: Issues in making a therapeutic choice: recombinant and/or human-derived products. *Haemophilia* 2001; 7: 89-90.
292. Aledort LM. Making a therapeutic choice: human versus recombinant fractions - can we do it? *Haemophilia* 2001; 7: Suppl. 1: 1-3.
293. Aledort LM, guest editor. Coagulation Therapy in the New Millennium. *Haemophilia* 2001; 7: Suppl. 1.
294. Salkowitz JR, Purvis SF, Meyerson H, Zimmerman P, O'Brien TR, Aledort L, Eyster ME, Hilgartner M, Kessler C, Konkle BA, White II GC, Goedert JJ, Lederman MM. Characterization of High-Risk HIV-1 Seronegative Hemophiliacs. *Clin Immunol* 2001; 98: 2: 200-211.
295. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, on behalf of the Factor VIII and Factor IX Subcommittee. Definitions in Hemophilia: Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Throm Haemost* 2001; 85: 560.
296. Brown SA, Aledort LM, Lee Ca, Barrowcliffe TW, Beeton K, Blanchette V, Bolland S, Goddard N, Goodeve A, Hoyer L, Kessler CM, Ljung R, Lollar P, Manco-Johnson M, Mariani G, Peerlinck K, and Rivard G. Meeting Report: Optimal treatment regimens for patients with bleeding disorders. *Haemophilia* 2001; 7: 313-320.

297. Leissinger C, Becton D, Cornell Jr. C, and Gill JC (for multicenter study investigators). High-dose DDAVP intranasal spray (Stimate®) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willbrand disease and symptomatic carriers of haemophilia A. *Haemophilia* 2001; 7: 258-266.
298. Aledort LM. Economics of hemophilia care. *Haemostasis* 2000; 30: 333-336.
299. Aledort LM. Adverse Reactions Related to rVIIa? *Am J Hematol* 2001; 67: 213.
300. Kulkarni R, Aledort LM, Berntorp E, Brackman HH, Brown D, Cohen AR, Ewing NP, Gringeri A, Gruppo R, Hoots K, Leissinger C, Peerlinck K, Poon M-C, and Wong W-Y. Therapeutic Choices for Patients With Hemophilia and High-Titer Inhibitors. *Am J Hematol* 2001; 67: 240-246.
301. Aledort LM. Can the costs of immune tolerance induction (ITI) be justified? *Int Monitor on Hemophilia* 2001; 9: 1: 23.
302. Astermark J, Aledort L, Berntorp E, and the Symposium Group. Meeting Report: Symposium in memory of Professor Inga Marie Nilsson. *Haemophilia* 2001; 6: 401-410.
303. Aledort LM. Hemophilia (Letter to the Editor). *N Engl J Med* 2001; 345: 14: 1066.
304. Doti CA, Gondolesi GE, Sheiner PA, Emre S, Miller CM, Aledort LM. Leukemia after Liver Transplant. *Transplantation* 2001; 72: 1643-1646.
305. Aledort L. Prophylaxis: when and how? *Int Monitor on Hemophilia* 2001; 9: 2: 19.
306. Aledort LM. The role of porcine factor VIII in the management of unexpected bleeding episodes. *Haemophilia* 2002; 8 (Suppl. 1): 17-19.
307. Tarantino M, Aledort L. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors. *Transfusion* 2001; 41: 1628-1629.
308. Aledort L. Hemophilia revisited. *Int. Monitor on Hemophilia* 2002; 10: 1: 40-41.
309. Diamondstone LS, Aledort LM, Goedert JJ for the Multicenter Hemophilia Cohort Study. Factors predictive of death among HIV-uninfected persons with haemophilia and other congenital coagulation disorders. *Haemophilia* 2002; 8: 660-667.
310. Brown SA, Aledort LM and Lee CA. Meeting Report. *Haemostasis: from bench to bedside. Haemophilia* 2002; 8: 685-693.
311. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, de Moerlose P, White II GC, Angiolillo AL, Luban NLC, Sherman KE, Manco-Johnson M, Preiss L, Leissinger C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A, for the Multicenter Hemophilia Cohort Study. End-stage liver disease in persons with hemophilia and transfusion-associated infections. *Blood* 2002; 100: 5: 1584-1589.
312. Aledort LM. Can Costs of Hemophilia Products be Curtailed? Not as we Do Business Today! *Thromb Haemost* 2002; 88: 4: 541.
313. Engels EA, Clark E, Aledort LM, Goedert JJ, Whitby D. Kaposi's sarcoma-associated herpesvirus infection in elderly Jews and non-Jews from New York City. *Intl J Epidemiol* 2002; 31: 946-950.
314. Aledort LM. Impact of prophylaxis in Europe: quality of life and economics. *Int Monitor on Hemophilia* 2002; 10: 2: 39-40.

315. Brown SA, Aledort LM, and the Round Table Group. Unresolved issues in prophylaxis. *Haemophilia* 2002; 8: 6: 817-821.
316. Aledort LM. Choice of replacement therapy for hemophilia (Letter to the Editor) *J Thromb Haemost* 2003; 1: 3: 596
317. Butler RB, Schultz JR, Forsberg AD, Brown LK, Parsons JT, King G, Kocik SM, Jarvis D, Schulz SL and Manco-Johnson M and the CDC Adolescent HBIEP Study Group. Promoting safer sex among HIV-positive youth with haemophilia: therapy, intervention, and outcome. *Haemophilia* 2003; 9:2: 214-222.
318. Aledort LM. Can pain predict joint outcomes in hemophiliacs? *Intl Monitor on Hemophilia* 2003; 11: 1: 39-40.
319. Leissinger C and Aledort L. Inhibitor Management: Prophylaxis. *Intl Monitor on Hemophilia* 2003; 11: 1: 3-6.
320. Aledort LM. Why Thrombin Generation? From Bench to Bedside. *Pathophysiol Haemost Thromb* 2003; 33: 2-3.
321. Aledort LM. Inter-country comparisons of factor VIII concentrate consumption and cost considerations. *Intl Monitor on Hemophilia* 2003; 11: 2: 21.
322. Aledort LM. Can orthopedic advances be made accessible for all hemophiliacs? *Intl Monitor on Hemophilia* 2003; 11: 2: 34.
323. Aledort LM. Hemophilia arthropathy continues to require major interventions. *Intl Monitor on Hemophilia* 2003; 11: 2: 36.
324. Brown SA, Aledort LM, and Lee CA. Meeting Report: Molecular challenges and viral diseases. *Haemophilia* 2003; 9: 727-737.
325. Aledort LM. Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: Are they appropriate and safe? Letter to the Editor. *J Thoracic & Cardiovascular Surgery* 2003; 126: 6: 2112-2113.
326. Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, and Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. *Haemophilia* 2004; 10: 63-68.
327. Aledort LM. Do We Need a Better Test? Can Thrombin Generation Be Useful? *Current Hematology Reports* 2004; 3: 75-76.
328. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. *Blood Reviews* 2004; 18: 101-113.
329. Aledort LM. Orthopedic outcome studies and cost issues. *Semin Thromb Hemost.* 2003; 29: 1: 55-60.
330. Aledort LM. Forum on AIDS, hepatitis and hemophilia. *J Thromb Haemost* 2004; 2: 521.
331. Aledort LM. Have stresses in hemophilia patients changed over time? *Intl Monitor on Hemophilia* 2004; 12: 1: 39.
332. Aledort LM. Do hemophilia boys behave differently at home and at school? *Intl Monitor on Hemophilia* 2004; 12: 1: 40-41.

333. Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. *J Thromb Haemost* 2004; 2: 861-862.
334. Aledort LM, Hayward CPM; Chen M-G, Nichol JL, and Bussel J for the ITP Study Group. Prospective Screening of 205 Patients with ITP, Including Diagnosis, Serological Markers, and the Relationship of Platelet Counts, Endogenous Thrombopoietin, and Circulating Anti-Thrombopoietin Antibodies. *Am J Hematol* 2004; 76: 205-213.
335. Tarantino MD, Aledort LM. Advances in Clotting Factor Treatment for Congenital Hemorrhagic Disorders. *Clin Advances in Hematol & Oncol* 2004; 2: 6: 363-368.
336. Theodore D, Fried MW, Kleiner DE, Kroner BL, Goedert JJ, Eyster ME, Faust SP, Sherman KE, Kessler CM, Francis C, Aledort LM. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. *Haemophilia* 2004; 10: 413-421.
337. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs factor VIII inhibitor bypass activity. *J Thromb Haemost* 2004; 2: 1700-1708.
338. Aledort LM. Hemophilia replacement products, clinical trials: inhibitors and pharmacokinetics – can they be done? . *J Thromb Haemost* 2004; 2: 1855-1856.
339. Aledort LM. Intracranial hemorrhage in hemophilia: long-term outlook. *Intl Monitor on Hemophilia* 2004; 12: 2: 14.
340. Monahan PE, Aledort LM, for the ad hoc Hemophilia Inhibitor Study Group. Factors Affecting Choice of Hemostatic Agent for the Hemophilia Patient With an Inhibitor Antibody. *Am J Hematol* 2004; 77: 4: 346-350.
341. Dave SP, Greenstein AJ, Sachar DB, Harpaz N, and Aledort L. Bleeding Diathesis in Amyloidosis With Renal Insufficiency Associated With Crohn's Disease: Response to Desmopressin. *Amer J Gastroenterology* 2002; 97: 1: 187-189.
342. Feldman BM, Babyn P, Doria AS, Heijnen L, Jacobson J, Kilcoyne R, Lundin B, Manco-Johnson M, McLimont M, Petrini P, Pettersson H, and Blanchette VS, on behalf of the IPSG. Meeting Report: Proceedings of the International Haemophilia Prophylaxis Study Group Meeting, November 2003, Montreal, PQ, Canada. *Haemophilia* 2005; 11: 58-63.
343. Brown SA, Aledort LM, and The Round Table Group. Meeting Report: Economic challenges in haemophilia. *Haemophilia* 2005; 11: 64-72.
344. Aledort LM. Platelet Bleeding Disorders and Approach to Their Management. *Current Hematology Reports* 2005; 4: 85-87.
345. Aledort LM. Plug the Hole. *Blood* 2005; 105: 7: 2621.
346. Sallah S, Aledort L. Treatment of patients with acquired inhibitors. *J Thromb Haemost* 2005; 3: 595-597.
347. Lundin, B, Babyn P, Doria AS, Kilcoyne R, Ljung R, Miller S, Nuss R, Rivard GE, and Pettersson H on behalf of the International Prophylaxis Study Group. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. *Haemophilia* 2005; 11: 109-115.
348. IPSG Steering Committee. Commentary: Magnetic resonance imaging as an evaluative tool in haemophilic arthropathy, on behalf of the Medical Advisory Board, World Federation of Haemophilia and the International Prophylaxis Study Group. *Haemophilia* 2005; 11: 107-108.

349. Participants of the *Cost of Blood Consensus Conference*, Charleston, SC, May 4-5, 2003. The Cost of Blood: Multidisciplinary Consensus Conference for a Standard Methodology. *Transfusion Med Reviews* 2005; 19: 1: 66-78.
350. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity – reply to a rebuttal. *J Thromb Haemost* 2005; 3: 819.
351. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity – reply to a rebuttal. *J. Thromb Haemost* 2005; 3: 822.
352. Mayer SA, Aledort LM. Thrombotic Microangiopathy: Differential Diagnosis, Pathophysiology and Therapeutic Strategies. *Mount Sinai J Med* 2005; 72: 3: 166-175.
353. Doria AS, Lundin B, Kilcoyne RF, Babyn PS, Miller S, Nuss R, Rivard G, Stephens D and Pettersson H. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: Expert MRI Working Group of the International Prophylaxis Study Group. *Haemophilia* 2005; 11: 245-253.
354. Aledort LM, Coates J. Can Managed Care Support Hemophilia in the 21st Century? *Amer J Hematol* 2005; 79: 172-173.
355. Bussel JB, Eldor A, Kelton JG, Varon D, Brenner B, Gillis S, Angiolillo A, Kulkarni R, Abshire TC, Kelleher J and the IGIV-C in ITP Study Group. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. *Thromb Haemost* 2004; 91: 4: 771-778.
356. Goedert JJ for the Second Multicenter Hemophilia Cohort Study. Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003. *Haemophilia* 2005; 11: 516-528.
357. Commentary: Magnetic resonance imaging as an evaluative tool in haemophilic arthropathy, on behalf of the Medical Advisory Board, World Federation of Haemophilia and the International Prophylaxis Study Group. *Haemophilia* 2005 11: 107-108.
358. Aledort LM, Goudemand J, and the Hemoleven Study Group. United States' Factor XI-Deficiency Patients Need a Safer Treatment. *Am J Hematol* 2005; 80: 4: 301-302.
359. Aledort LM. Chronic disease and the disability paradox. *Intl Monitor on Hemophilia* 2004; 13: 2: 41-42.
360. Sieger L and Aledort L. Inhibitor challenges in the paediatric setting (Letter to the Editor). *Haemophilia* 2006; 12: 106-107.
361. Allen G and Aledort L. Therapeutic Decision-Making in Inhibitor Patients. *Am J Hematol* 2006: 81: 71-72.
362. Aledort L, Ljung R, and Blanchette V, on behalf of the International Prophylaxis Study Group (IPSG). Are randomized clinical trials the only truth? Not always. *J Thromb Haemost* 2006; 4: 503-504.
363. Aledort LM. Can we prevent inhibitors in mild and moderate factor VIII-deficient patients? (Letter to the Editor). *J Thromb Haemost* 2006: 4: 914.
364. Feldman BM, Pai M, Rivard GE, Israels S, Poon M-C, Demers C, Robinson S, Luke K-H, Wu JKM, Gill K, Lillcrap D, Babyn P, McLimont M, Blanchette VS, on behalf of the Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe

- hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. *J Thromb Haemost* 2006; 4: 1228-1236.
365. Aledort LM. Do hemophilia carriers bleed? Yes. *Blood* 2006; 108: 1: 6.
366. Aledort LM. MedWatch: an important instrument for postlicensing surveillance. *J Thromb Haemost* 2006; 4: 1637.
367. Altomare I, Desman G, and Aledort LM. Echinocytosis – An Unusual Manifestation of Hemangioma. *Am J Hematol* 2006; 81: 532-534.
368. Aledort LM and Lee CA. Meeting Report: Coagulation deficiencies: a look to the future. *Haemophilia* 2006; 12: 531-540.
369. Bussell JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JSS, Wiznitzer I, Kelly R, Chen C-F, Nichol JL. AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP. *N Engl J Med* 2006; 355: 1672-1681.
370. Aledort LM. Are recombinant factor VIII products more likely to induce inhibitors than human-derived products? *Intl Monitor on Hemophilia* 2006; 14: 2: 33.
371. Aledort LM. Can recombinant factor VIII be compared with human-derived factor VIII in ITI in small studies? *Intl Monitor on Hemophilia* 2006; 14: 2: 34.
372. Di Paola J, Aledort L, Britton H, Carcao M, Grabowski E, Hutter J, Journeycake J, Kempton and Leissinger C. Application of current knowledge to the management of bleeding events during immune tolerance induction. *Haemophilia* 2006; 12: 591-597.
373. Aledort LM. Hemophilia treatment challenges in the XXIst century. *Haematologica* (Spanish edition) 2006; 91: Suppl. 3: 1.
374. Aledort LM. Progress in the safety of plasma-derived factor VIII and factor IX concentrates: a reality. *Haematologica* (Spanish edition) 2006; 91: Suppl. 3: 2-5.
375. Aledort LM. Type 1 von Willebrand disease: can phenotype predict bleeding? *Intl Monitor on Hemophilia* 2007; VWD Issue 2: 27-28.
376. Aledort LM. HIV and hemophilia. *J Thromb Haemost* 2007; 5: 607-608.
377. Aledort LM. Can surrogate markers obviate liver biopsy in hemophilia patients with hepatitis C virus? *Intl Monitor on Hemophilia* 2007; 15: 1: 34-35.
378. Goedert JJ, Chen BE, Preiss L, Aledort LM, and Rosenberg PS for the Second Multicenter Hemophilia Cohort Study. Reconstruction of the Hepatitis C Virus Epidemic in the US Hemophilia Population, 1940-1990. *Am J Epidemiol* 2007; 165: 1443-1453.
379. Carcao MD and Aledort LM on behalf of the Round Table Group. Meeting Report: Prophylaxis in the haemophilia population-optimizing therapy. *Haemophilia* 2007; 13: 227-232.
380. Kraut EH, Aledort LM, Arkin S, Stine KC, and Wong W-Y. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. *Haemophilia* 2007; 13: 508-517.
381. Tarantino M, Ma A, and Aledort L. Safety of human plasma-derived clotting factor products and their role in Haemostasis in patients with haemophilia: meeting report. *Haemophilia* 2007; 13: 663-669.

382. Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, and Blanchette VS. The economics of haemophilia prophylaxis: governmental and insurer perspectives. PROCEEDINGS OF THE SECOND INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) SYMPOSIUM. *Haemophilia* 2007; 13: 745-749.
383. Aledort LM, Salama A, Kovaleva L, Robak T, Newland AD, Nugent DJ, Brenner B, and Zenker O, for the International Anti-D Study Group. Efficacy and Safety of Intravenous anti-D Immunoglobulin (Rhophylac®) in Chronic Immune Thrombocytopaenic Purpura. *Hematology* 2007; 12 (4): 289-295.
384. Lee CA, Aledort LM. Meeting Report – Coagulation Deficiencies: A look to the future. *Haemophilia* 2007; 13: 750-757.
385. Aledort LM. History of haemophilia. *Haemophilia* 2007; 13 (Suppl 5): 1-2.
386. Aledort LM. Transfusion-transmitted diseases: liver disease as a consequence of HCV. *Intl Monitor on Hemophilia* 2007; 15: 2: 34.
387. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovic FT, deWolf TM, Bourgeois E, Guthrie Jr. TH, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard J-F, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. *Lancet* 2008; 371: 395-403.
388. Rivard GE, Aledort L, and the Alphanate Surgical Investigators. Efficacy of Factor VIII/von Willebrand factor concentrate Alphanate® in preventing excessive bleeding during surgery in subjects with von Willebrand disease. *Haemophilia* 2008; 14: 271-275.
389. Aledort LM. Factor eight inhibitor bypassing activity (FEIBA) – addressing safety issues. *Haemophilia* 2008; 14: 39-43.
390. Aledort LM. Hemophilia lives: the impact of prophylaxis. *Blood* 2008; 111: 4: 1752-1753.
391. Aledort LM. Should epidural analgesia be given to type 1 VWD parturients? *Intl Monitor on Hemophilia* 2008; VWD No. 3: 23.
392. Cromwell C and Aledort LM. Recent Clinical Advances in Coagulopathies. *US Hematology* 2007: 11-13.
393. Aledort LM and Cromwell C. The Impact of Factor VIII/von Willebrand Factor Products in Inhibitor Development and Management of Patients with Hemophilia A with Inhibitors. *US Hematology* 2007: 14-16.
394. Sealove BA, Aledort LM, Stacy CB, and Halperin JL. Case Report: Recurrent Orthostatic Global Amnesia in a Patient with Postoperative Hyperfibrinogenemia. *J Stroke and Cerebrovascular Diseases* 2008; 17: 4: 241-243.
395. Aledort LM. Vascular abnormalities in hemophilia patients with and without inhibitors. *Intl Monitor on Hemophilia* 2008; 16: 2: 22-23.
396. Cromwell C, Tarantino M, Aledort LM. Safety of anti-D during pregnancy. *Am J Hematol* 2009; 261-262.

397. Aledort L. A cytokine for the treatment of von Willebrand disease. *Intl Monitor on von Willebrand Disease* 2009; VWD No. 4: 43.
398. Lee CA and Aledort LM. Meeting Report: Bleeding and Clotting: new therapies and old issues revisited. *Haemophilia* 2009; 15: 592-596.
399. Olowokure O, Fishman M, Cromwell C and Aledort L. Letter to the Editor: DDAVP for von Willebrand menorrhagia – severe hyponatraemia, haemolysis, seizure, coma!! Caution. *Haemophilia* 2009; 15: 837.
400. Aledort LM. Commentary: Mild and moderate factor VIII deficiency: inhibitor risks. *J Thromb Haemost* 2009; 7: 928-929.
401. Aledort L. An animal model shows that cytokines play a key role in bleeding hemophilia joints. *Intl Monitor on Hemophilia* 2009; 17: 2: 19-20.
402. Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, and Ewenstein B. Emerging clinical concerns in the ageing haemophilia patient. *Haemophilia* 2009; 15: 1197-1209.
403. Zakarija A and Aledort L. How we treat: Venous thromboembolism prevention in haemophilia patients undergoing major orthopaedic surgery. *Haemophilia* 2009; 15: 1308-1310.
404. Aledort LM. Commentary: To bleed or not to bleed: is that a question? *J Thromb Haemost* 2010; 8: 1: 81-82.
405. Misra D, Bednar M, Cromwell C, Marcus S, Aledort L. Manifestations of superwarfarin ingestion: A plea to increase awareness. *Am J Hematol* 2010; 85: 5: 391-392.
406. Stanca CM, Fiel MI, Aledort L, Cohen E, del Rio Martin, J, Schiano TD. Factors Associated with Persistent Thrombocytopenia after Liver Transplantation. *Transplantation Proceedings* 2010; 42: 1769-1773.
407. Aledort LM. How much can we learn from a data collection Registry? *Intl Monitor on Hemophilia* 2010; 18: 2: 45-46.
408. Aledort LM. Off-Label Use of Recombinant Activated Factor VII -Safe or Not Safe? *N Engl J Med* 2010; 363: 19: 1853-1854.
409. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, and Nichol JL. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). *J Thromb Haemost* 2010; 8: 1372-1382.
410. Misra D, Aledort L. Recurrent miscarriages: Caution regarding development of clinical trials using low molecular weight heparin and pregnancy. *Am J Hematol* 2011; 86: 2: 235.
411. Sanz MA, Aledort L, Mathias SD, Wang X, Isitt JJ. Analysis of EQ-5D Scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). *Value in Health* 2011; 14: 90-96.
412. Aledort LM. Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment. *J Thromb Haemost* 2011; 9: 423-7.
413. Bar-Chama N, Snyder S, Aledort L. Sexual evaluation and treatment of ageing males with haemophilia. *Haemophilia* 2011: 1-9.

414. Kremyanskaya M and Aledort L. Acquired hemophilia: We now see it with myeloproliferative neoplasms. *Am J Hematol* 2011; 86: 3: 329-330.
415. Aledort LM. Do clotting genes protect von Willebrand disease patients from bleeding? *Intl Monitor on von Willebrand Disease* 2011; 6: 36.
416. Aledort LM. Treatment of Factor XI Deficiency. *Clin Adv Hematol Oncol* 2011; 9: 305-306.
417. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. *J Thromb Haemost* 2011; 9: 2180-2192.
418. Aledort LM, Navickis RJ, Wilkes MM. Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII. *J Thromb Haemost* 2011; 9: 2325-2333.
419. Aledort LM. Is tailored prophylaxis the right way forward for hemophilia patients? *Intl Monitor on Hemophilia* 2011; 19: 1: 19-20.
420. Bar-Chama N, Snyder S, and Aledort L. Sexual evaluation and treatment of ageing males with haemophilia. *Haemophilia* 2011; 17: 875-883.
421. Fogarty PF, Olin JW, Kessler CM, Konkle BA and Aledort LM. An algorithmic approach to peripheral artery disease in hemophilia: extrapolation of management principles from noncoagulopathic patients. *Bood Coagul Fibrinolysis* 2011; 23: 23-29.
422. Kurth M, Puetz J, Kouides P *et al*. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. *J Thromb Haemost* 2011; 9:2229-34.
423. Sheth S, Soff G, Mitchell B, Green D, Kaicker S, Fireman F, Tugal O, Guarini L, Giardina P and Aledort L. Managing incidentally diagnosed isolated factor VII deficiency perioperatively: a brief expert consensus report. *Expert Rev Hematol* 2012; 5: 1: 47-50.
424. Aledort L, Bullinger M, von Mackensen S, Wasserman J, Young NL, Globe D, on behalf of the Health Related Quality of Life Expert Working Group of the International Prophylaxis Study Group. Why should we care about quality of life in persons with haemophilia? *Haemophilia* 2012; DOI: 10.1111/j.1365-2516.2012.02771.x
425. Lipshitz J, Chelliah T, and Aledort L. A case of factor V inhibitor with complete correction of the PT and aPTT upon mixing. *Am J Hematol* 2012; 87:3: 313-315.
426. Aledort LM. Another role for the VW molecule. *Haemophilia* 2012; 18: 246-247.
427. Aledort LM. VWD prophylaxis can achieve results similar to hemophilia. *Intl Monitor VWD* 2012; 7: 40-41.
428. Cromwell C, Aledort LM. FEIBA: A Prohemostatic Agent. *Semin Thrombo Hemost* 2012; 38: 3: 265-267.
429. Aledort LM. Current treatments of hemophilia and von Willebrand disease are not highly evidence-based. *Int Monitor on Hemophilia* 2012; 20:1: 17-18.
430. Kisker C, Aledort L and Farin H. Efficacy evaluation of products for treatment of bleeding episodes. *Haemophilia* 2012; 18: 5: e367.

431. Gringeri A, Lambert T, Street A and Aledort L on behalf of the Adolescent/Adult Prophylaxis Expert Working Group of the International Prophylaxis Study Group. Tertiary prophylaxis in adults: is there a rationale? *Haemophilia* 2012; 18: 5: 722-728.
432. Pintova S, Bhardwaj AS, Aledort LM. IVIG – A Hemolytic Culprit. *N Engl J Med* 2012; 367: 10: 974-976.
433. Carcao M, Malkin D, and Aledort L. Symposium on Congenital and Acquired Bleeding Disorders in Children (In Honor of the Lifetime accomplishments of Dr. Victor S. Blanchette in Pediatric Hematology). *Pediatr Blood Cancer* 2013; 60: S1: 1.
434. Rangarajan S, Aledort L. Will Gene Therapy Trump Factor Treatment in Haemophilia? *Expert Rev. hematol.* 6(1), 43-48 (2013)
435. Elliott B and Aledort L. Restoring Hemostasis: Fibrinogen Concentrate vs Cryoprecipitate. *Expert Rev Hematol.* 6(3), 277-286 (2013)
436. Oldenburg J, Jimenez-Yuste V, Peiro-Jordan R, Aledort L., and Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicenter international study with Von Willebrand Factor- containing plasma-derived Factor VIII concentrate. *Haemophilia.* 2014 Jan;20(1):83-91.
437. Aledort LM, The Effect of a Specialized Case Management Program on the Cost of Factor Replacement Use in Patients with Bleeding Disorder (letter to editor) *Haemophilia* (2014) , 20. E222-E242
438. Aledort LM, Ljung MD, Rolf, Kenneth Mann, PhD, Steve Pipe, MD, Factor VII Therapy for Hemophilia A: Current and Future Issues. *Expert Review of Hematology* 2014 Vol 7, Iss. 3.
439. Binder, A., and Aledort L. "Glanzmann's thrombasthenia: meeting the anticoagulation challenge." *Haemophilia* (2015).
440. Aruch DB, Aledort L. Fatal Hematologic Alphabet Soup: A Complicated Case with Overlapping Features of TTP, AIHA, and HLH. *J Hematol Thrombo Dis.* 2015; 3:202. doi: 10.4172/2329-8790.1000202
441. Aledort LM. Are some recombinants more immunogenic than others? One needs a careful look before a conclusion. *The International Monitor on Hemophilia* 2015; 23: 43–44.
442. Bussel JB, Kuter DJ, Aledort L, Kessler C, Cuker A, Pendergrass K, Tang S, McIntosh J. A Randomized Trial of avatrombopag (E5501), an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. *Blood* Jan 2014. Doi: 10.1182/blood-2013-07-514398
443. Michel M, Wasser J, Godeau B, Aledort LM, Cooper N, Tomiyama Y, KhellaMF, Wang X, Woodard P. Efficacy and Safety of the thrombopoietin receptor agonist Romiplostim in patients aged ≥ 65 Years with Immune Thrombocytopenia. *Ann Hematol.* Aug 2015. DOI: 10.1007/s00277-015-2485-x
444. Aledort LM, The evolution of comprehensive haemophilia care in the United States: Perspective from the frontline. *Haemophilia* (2016) 1–8 DOI: 10.1111/hae.12970.
445. Jennifer A. Frontera, J. Javier Provencio, Fatima A. Sehba, Thomas M. McIntyre, Amy S. Nowacki, Errol Gordon, Jonathan M. Weimer, Louis Aledort, The Role of Platelet Activation and Inflammation in Early Brain Injury following Subarachnoid Hemorrhage. *Neurocritical Care*, pp 1–10, DOI: 10.1007/s12028-016-0292-4

446. Aledort LM, Recht M, Kulkarni R & Kobrinsky N. Adult PUPs Remain a Significant Therapeutic Challenge (letter to the editor). *Journal of Thrombosis and Haemostasis*. *J Thromb Haemost*. 2016 Oct;14(10):2075-2076. doi: 10.1111/jth.13434.
447. Alfonso Iorio, Louis Aledort, Lessons Learned Assessing Immunogenicity of B Domain Deleted recombinant factor VIII (letter to the editor). *Journal of Thrombosis and Haemostasis*. Submitted
448. Aledort LM., MD1, Tammuela C. Singleton, MD2, Paula J. Ulsh, BSN3. Icahn School of Medicine, New York, NY; Tulane University, New Orleans, LA; Kedrion Biopharma, Fort Lee, NJ. Treatment of Congenital Thrombotic Thrombocytopenia Purpura: A New Paradigm. *J Pediatric Hematology Oncology*. 2017 Oct;39 (7):524-527.
449. Carcao M, Avila L, Leissing C, Blanchette V, Aledort L. An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia. *Haemophilia*. 2017 Sep;23(5):e447-e450. doi: 10.1111/hae.13238. Epub 2017 Apr 21. PMID: 28429874
450. Carcao M, Avila L, Leissing C, Blanchette V, Aledort L. An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia. *Haemophilia*. 2017 Sep;23(5):e444-e447. doi: 10.1111/hae.13222. Epub 2017 Apr 24. PMID: 28439934
451. Aledort, L. Summary and comment on Von Willebrand disease requires major orthopedic surgery. *The International Monitor on von Willebrand disease*. Submitted to *Haemophilia* 2016.
452. Aledort, L. & Coates J. EHL (Extended Half-Life) Products, What Are They Costing? *Annals of Blood Research*; Published: 28 Jul, 2017.
453. Aledort L. An Alternative Model for Hemophilia Care Delivery Is it Viable? Yes. Submitted to *Haemophilia* 2017.
454. Aledort, L. Lend Lease: A Creative Program to Provide Hemophilia Care in Albania. *International Journal of Hematology and Blood Disorders*. Received: 25 April, Accepted: 5 May, 2017; Published: 29 September, 2017.
455. Aledort LM & Ewenstein BM (2017) Emicizumab Prophylaxis in Hemophilia with Inhibitors. *N Engl J Med*. 2017 Nov 30; 377 (22):2193. doi: 10.1056/NEJMc1712683.
456. Carcao M, Lambert T, Leissing C, Escuriola-Ettingshausen C, Santagostino E, Aledort L. International Prophylaxis Study Group (IPSG). Prophylaxis re-visited: the potential impact of novel factor and non factor therapies on prophylaxis. *Haemophilia*. 2018 Jul 10. doi: 10.1111/hae.13558. PMID: 29989273
457. Glassberg J, Rahman AH, Zafar M, Cromwell C, Punzalan A, Badimon JJ, Aledort L. Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis. *J Immunol Methods*. 2018 Feb;453:11-19. doi: 10.1016/j.jim.2017.07.014. Epub 2017 Jul 29. PMID: 28760671.
458. Aledort, L. The Ongoing Imperative for Immune Tolerance Induction in Inhibitor Management. Accepted by *Haemophilia* 2018.
459. Hart, DP, Kessler C, Aledort, L. (2018). Re-personalisation and stratification of Haemophilia care. submitted.

460. Carcao M, Lambert T, Leissinger C, Escuriola-Ettinghausen C, Santagostino E, Aledort L on behalf of the International Prophylaxis Study Group (IPSG). Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis. *Haemophilia*. 30 May 2018 DOI: 10.1111/hae.13558.
461. Aledort L, Milligan S, Watt M, Booth J. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States. *Journal of Managed Care and Specialty Pharmacy*. Accepted December 2019.
462. Aledort L, Carpenter S, Cuker, Kulkarni, Recht, Young G, Leissinger Why Plasma Derived Factor VIII? *Hemophilia* Vol 25 issue #3 E183-185 Submitted May 2019
463. Rainchwar S, Karnik S, Aledort L Plasmodium Vivax Malaria: An unusual Presentation of Atypical Hemolytic Uremic Syndrome Submitted September 2019
464. Aledort L. Emicizumab Deaths Associated with Emicizumab in Patients with Hemophilia A, *NEJM* 2019 Nov 7;381(19):1878-1879 Published
465. Hart D, Kessler CM, Aledort L. Re-personalization and stratification of haemophilia care in an evolving treatment landscape. *Hematology*. 2019 Dec;24(1):737-741 Published
466. Louis Aledort, Pier Mannuccio Mannucci, Wolfgang Schramm, Michael Tarantino - Factor VIII replacement is still the standard of care in haemophilia A. *Blood Transfus*. 2019 Nov;17(6):479-486 Published
467. Aledort L. Emicizumab Deaths Associated with Emicizumab in Patients with Hemophilia A, *NEJM* 2020 Published

Bibliography

Books and Chapters:

1. Aledort LM: Platelet aggregation in the circulating platelet, in Johnson S (ed): Circulating platelet. New York, Academic Press, Inc., 1971, pp 259-281.
2. Puszkin E, Aledort LM: Platelets, biochemistry and physiology, in Root WS, Berlin NI (eds): Physiologic Pharmacology. New York, Academic Press, Inc., 1974, pp 177-198.
3. Aledort LM, Taub R, Burrows L, Leiter E, Glabman S, Haimov M, Nirmul G, Berger S: Use of inhibitors of platelet function in renal rejection phenomena, in Sherry S, Scriabine A (eds): Platelets and Thrombosis. Baltimore, University Park Press, 1974, pp 264-271.
4. Aledort LM, Berger S, Goldman B, Puszkin E: Antiserotonin and antihistamine drugs as inhibitors of platelet function, in Sherry S, Scriabine A (eds): Platelets and Thrombosis. Baltimore, 1974, pp 149-159.
5. Aledort LM: Hemophilia products - a case for continued plasmapheresis. Schnabel F, Mannucci P (eds): #9 Bulletin of the WFH. 1975.
6. Berger S, Aledort LM: The use of analgesics and anti-inflammatory agents in hemophilia. Handbook of Hemophil Part II, Excerpta Medica. 1975, pp 701-714.
7. Aledort LM: Present and future trends in medical management - the primary physician's expectations of psycho-social services, in Agle DP (ed): Proceedings of the workshop on mental health services in the comprehensive care of the hemophiliac. Chicago, 1976, pp 13-14.
8. Aledort LM: The cause of death in hemophiliacs. Fratantoni JC, Aronson DL (eds): Unsolved therapeutic problems in hemophilia. Bethesda, 1976; US Dept of Health, Education and Welfare DHEW publication No. (NIH) 77-1089, pp 9-14.
9. Aledort LM: Blood clotting abnormalities in liver disease, in Popper H, Schaffner F (eds): Progress in liver diseases. New York, Grune & Stratton Inc., 1976, pp 350-362.
10. Aledort LM: Platelets and thromboembolism, in Donoso E, Haft J (eds): Anticoagulation, and acetylsalicylic acid. New York, Stratton Intercontinental Med Book Corp., 1976, vol 2, pp 156-165.
11. Aledort LM: Hemophilia care: its cost, in Hilgartner M (ed): Hemophilia in children. Progress in pediatric hematology/oncology. Massachusetts, Publishing Sciences Group Inc., 1976, vol 1, pp 201-205.
12. Levine PH, Aledort LM: Surgery in the hemophiliac. The National Hemophilia Foundation series on the treatment of hemophilia, 1977, pp 1-9.
13. Aledort LM: Hemophilia: impact on blood programs and blood products, in Morrison F (ed): Hemophilia. Washington, D.C., American Association of Blood Banks, 1977, pp 61-70.
14. Aledort LM: Current management - A physician's manual. The National Hemophilia Foundation series on the treatment of hemophilia, 1978.
15. Aledort LM: Hemophilia, in Hubbell R (ed): Advances in blood transfusion. American Blood Commission, 1979, pp 11-17.

16. Aledort LM for the P.A.R.I.S. Reinfarction Study: The persantine-aspirin reinfarction study, in Fumagalli R, Kritchevsky D, Paoletti R (eds): *Drugs affecting lipid metabolism*. Elsevier/North-Holland Biomedical Press, 1980, pp 177-180.
17. Aledort LM: Definition of comprehensive care, in *Proceedings of 2nd International Symposium on Hemophilia Treatment*, Tokyo, 1981, pp 1-5.
18. Aledort LM: Home care in the United States, in *Proceedings of 2nd International Symposium on Hemophilia Treatment*, Tokyo, 1981, pp 59-63.
19. Gorlin R, Aledort LM (eds): *Proceedings of the Symposium on Grand Rounds in Medicine: Recognition and Management of Thromboembolic Disorders*, New York, Professional Postgraduate Services, Inc., October 30-31, 1981.
20. Aledort LM (ed): *Proceedings of the Symposium on Grand Rounds in Medicine: Recognition and Management of Thromboembolic Disorders*, Number 2 in a Series on Principles of Anticoagulant Therapy, New York, Professional Postgraduate Services, Inc., 1982.
21. Aledort LM, Taub S, Diaz M: Problems of Anti-A and Anti-B in concentrates, in Hilgartner, M (ed): *Hemophilia in the Child and Adult*, edition 2. New York, Masson Publishing USA, Inc., 1982, pp 181-185.
22. Aledort LM, Diaz M: The cost of care for hemophiliacs, in Hilgartner M (ed): *Hemophilia in the Child and Adult*, edition 2. New York, Masson Publishing USA, Inc., 1982, pp 187-193.
23. Aledort LM, Goodnight SH: Hemophilia treatment: its relationship to blood products, in Brown E (ed): *Progress in Hematology*, New York, Grune & Stratton Inc., 1981, vol XII, pp 125-141.
24. Aledort LM, Brach I: The cost of care for hemophiliacs, in Forbes CD, Lowe GDO (eds): *International Symposium on Unresolved Problems in Hemophilia*, Glasgow, 1980, Boston, MTP Press Ltd, 1982, pp 79-86.
25. Aledort LM, Hilgartner MW: Treatment and care of haemophiliacs and other inherited coagulation disorders, in Hollan SR (ed): *Educational Manual of the ISH/ISBT International Congress*, Budapest, 1982, pp 78-82.
26. Berman LB, Aledort LM: Anticoagulation in pregnancy: diagnosis and management of maternal and fetal disease. Alan R. Liss, Inc., 1982, pp 261-272.
27. Aledort LM (ed): *Proceedings of the symposium on grand rounds in medicine: Recognition and management of thromboembolic disorders*, part 3 on proper use of antiplatelet and anticoagulant drugs, New York, Professional Postgraduate Services, Inc., 1983.
28. Aledort LM: AIDS and blood and blood products, in Blackistone and Assoc (ed): *Plasma Forum '83 Acquired Immune Deficiency Syndrome Segment*. Maryland, American Blood Resources Assoc, 1983, pp 219-227.
29. Rand JH, Fruchtman SM, Aledort LM: Hemorrhagic disorders in pregnancy, edition 3, in Cherry SH, Berkowitz RL, Kase NG (eds): *Medical, Surgical and Gynecologic Complications of Pregnancy*, Baltimore, Williams & Wilkins, 1985, pp 241-252.
30. Aledort LM, Cohen M, Hilgartner M, Lipton R: Treatment of hemophiliacs with inhibitors: Cost and effect on blood resources, in Hoyer L (ed): *Factor VIII Inhibitors*. New York, Alan R Liss, Inc., 1984, pp 353-365.

31. Aledort LM: Opportunistic infections in hemophiliacs, in Landbeck G (ed): Proceedings of the First German Round-Table Discussion on AIDS and its Implication in Hemophiliacs. Stuttgart, F.K. Schattauer, 1984, pp 31-42.
32. Hilgartner MW, Aledort LM: Profilnine for treatment of hemophilia A patients with inhibitors to factor VIII. Presented at American Society of Hematology, December 1984.
33. Aledort LM: The disease - hematologic considerations - past and present, in Pettersson H, Gilbert M (eds): Diagnostic Imaging in Hemophilia. New York, Springer-Verlag, 1985, pp 1-7.
34. Hilgartner MW, Aledort LM, Giardina PJV: Thalassemia and hemophilia, in Hobbs N, Perrin JM (eds): Issues in the Care of Children with Chronic Illness. Jossey-bass, 1985, pp 299-323.
35. Aledort LM: Current management in the treatment of hemophilia - A physician's manual. The National Hemophilia Foundation Series on the Treatment of Hemophilia, 1986.
36. Aledort LM: Testimony for public briefing meetings of the Advisory Council of the NHLBI, Bethesda, Maryland, May 3, 1985. NHLBI Blood Advisory Council Public Briefings, 1985, A Report on the Meetings and Statements for the Record: B-1.
37. Aledort LM, Brach I: The cost of care for hemophiliacs, in Hilgartner M, Pochedly C (eds): Hemophilia in the Child & Adult, Third Edition, New York, Raven Press, 1989, pp 137-147.
38. Aledort LM: The future, in Madhok R, Forbes CD, Evatt BL (eds): Blood, Blood Products and AIDS. Chapman and Hall, London, 1987, pp 217-223.
39. Aledort LM: Much to know. Keio Journal of Medicine, 1986, 35, pp 291-297.
40. Damm C, Aledort LM: AIDS-free is easier to say than to prove. New York Times letter, May 1, 1987.
41. Hearing before the Select Committee on Children, Youth, and Families, House of Representatives, One Hundredth Congress, First Session (June, 1987) (testimony of Louis M. Aledort, MD) 1988, pp 62-66.
42. Aledort LM: Non-A, Non-B hepatitis viruses in hemophiliacs. Complications of Hemophilia Therapy: New Strategies for Risk Reduction, Highlights from a Symposium. New York, Audio Visual Medical Marketing Inc., 1988.
43. Aledort LM: The hemophilia model. Proceedings from the Surgeon General's Conference: Growing up and getting medical care, youth with special health care needs. March 13-15, 1989, pp 33-34.
44. Aledort LM, Weiss H, Parker CT, Levi JR, Simon R: Life-style interventions in the young. The Handbook of Health Behavior Change. 1990, pp 293-314.
45. Aledort LM: Experience with prophylactic treatment in the USA. Clinical benefits; a multi-centre view. Factor VIII Purity and Prophylaxis. Royal Society of Medicine, 1991, 25, pp 26-31.
46. Aledort LM: Safety and antigenicity of recombinant factor VIII in previously untreated patients. Recombinant Factor VIII and the Management of Hemophilia. Sponsored by Miles/Cutter Biological. 1991, pp 25-26.
47. Rand JH, Fruchtmann SM, Aledort LM: Disorders of hemostasis function in pregnancy, in Cherry SH, Markatz IR (eds): Complications of pregnancy: Medical, Surgical, Gynecologic, Psychosocial, and Perinatal. Fourth Edition Williams & Wilkins, 1991 pp 846-861.

48. Aledort LM: A safe approach to treatment of factor IX-deficient patients. *Seminars in Hematology* 1991, pp 1-24.
49. Aledort LM: Introduction (AIDS), in Alt FW (ed): *Immunology in the 21st Century (Proceedings of the 75th Anniversary Symposium, The Irvington Institute for Medical Research)*. Sigma Chemical Company, 1992, pp 145-146.
50. Aledort LM: Challenges in future hemophilia care, in Madhok R, Forbes CD, Evatt BL (eds): *Blood, Blood Products and HIV, Second Edition*, Chapman & Hall, 1993, pp 265-270.
51. Aledort LM: Introduction and overview of treatment, in Miescher PA, Jaffe ER (eds): *Seminars in Hematology - Prophylaxis: A future therapy for hemophilia*. W.B. Saunders Company/Harcourt Brace & Company, 1993, pp 1-2 & 24-25.
52. Seremetis SV, Aledort LM: Long-term effects of factor replacement - new challenges, in Duthie RB, Rizza CR, Giangrande PLF, Dodd CAF (eds): *The Management of Musculoskeletal Problems in the Haemophilias*. Second Edition, Oxford, Oxford University Press, 1994, pp 265-272.
53. Aledort LM: Impact of prophylaxis on product utilization in Europe and the United States, in *Prophylactic Treatment of Hemophilia A and B: Current and Future Perspectives*. Science & Medicine, 1994, pp 116-118.
54. Aledort LM (ed): *Factor VIII inhibitor treatment: Strategies for the Continuing Challenge*. Supplement to *Seminars in Hematology*. W.B. Saunders Company/Harcourt Brace & Company, 1994, 31:2:4(suppl).
55. Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White II GC (eds): *Inhibitors to coagulation Factors*, Plenum Press, 1995.
56. Aledort LM: *Treatment of hemophilia: Prophylaxis*. Proceedings of the Symposium on Advances in the Treatment of Hemophilia and von Willebrand Disease, Berkeley, California, June 25-26, 1994. Alpha Therapeutic Corp.
57. Kessler CM, Aledort LM: The economics of immune tolerance and treatment of hemophiliacs with inhibitors, in Mariani G, Brackmann HH (eds): *Immune Tolerance and the Treatment of Hemophiliacs with an Inhibitor*. *Vox Sang* 1994;70:1(suppl):74-76.
58. Aledort LM: Inhibitors to coagulation: Can we afford immune tolerance induction regimens, in Mariani G, Brackmann HH (eds): *Immune Tolerance and the Treatment of Hemophiliacs with an Inhibitor*. *Vox Sang* 1994;70:1(suppl):77-78.
59. Seremetis SV, Aledort LM: Nasal spray desmopressin: Laboratory and clinical implication, in Mariani G, Mannucci PM, Cattaneo M (eds): *Desmopressin in Bleeding Disorders*. Plenum Press 1993;325-332.
60. Forbes CD, Aledort LM, Madhok R (eds): *Hemophilia*. Chapman & Hall. London. 1997.
61. Aledort LM: The treatment of hemophilia: Comprehensive hemophilia care, in Forbes CD, Aledort LM, Madhok R (eds): *Hemophilia*. Chapman & Hall. London. 1997.
62. Aledort LM: The future, in Rizza CR, Lowe GDO (eds): *Haemophilia and other Inherited Bleeding Disorders*. WB Saunders Company. UK. 1997.
63. Aledort LM, Ford DM: Hemophilia A; Therapeutics Today. CME Article. Centeon. 1999.

64. Aledort LM (guest editor), White II GC (co-editor). Challenges in the Treatment of Haemophilia with Inhibitors. *Haemophilia* 1999; 5: Suppl. 3.
65. Aledort LM (guest editor). Unexpected Bleeding Disorders: Identification, Diagnosis and Management. Proceedings of a Corporate Symposium preceding the 41st Annual Meeting of the American Society of Hematology, New Orleans. *Clinical and Laboratory Haematology* 2000; 22 (Suppl. 1).
66. Aledort LM. Experiences with Monoclonal Antibody Purified Factor VIII Concentrates in the Treatment of Haemophilia A in the USA. *Coagulation Factors: Current Issues. Highlights of a scientific meeting, Seoul, S. Korea, December 2000. Aventis Behring / Excerpta Medica Asia Ltd.* 2001.
67. Aledort LM, with an overview by. Treatment of hemophilia patients with factor VIII inhibitors: Proceedings of a consensus panel. CME program. *Medical Education Resources / Materia Medica-Creative Annex / Nabi* 2001.
68. Aledort LM. Platelet-Mediated Bleeding Disorders, in Rakel and Bope (eds): *Conn's Current Therapy* 2002. WB Saunders UK: 2002: 394-397.
69. Aledort LM, Green D, and Teitel JM. Unexpected Bleeding Disorders. *American Society of Hematology Education Program Book. Hematology* 2001.
70. Aledort LM. Policy Alternatives in Transfusion Medicine (ed. by AuBuchon JP, Petz L, and Fink A.): Book Review. *AABB News* May / June 2002.
71. Aledort LM. Foreword. *Textbook of Hemophilia* (ed. Lee CA, Berntorp EE, Hoots WK). 2005. Blackwell Publishing.
72. Cromwell C and Aledort LM. History of Hemophilia: Current and Future Issues in Hemophilia Care. (ed. Rodríguez-Merchán EC and Valentino LA) 2011 Wiley-Blackwell.
73. Aledort LM, and Etra A. Coagulation Disorders and thrombocytopenia in the Cardiac ICU Patient. *The Cardiac ICU Book*. 2017 Accepted
74. Langer, AL, Etra A, Aledort L. Evaluating the safety of emicizumab in patients with Hemophilia A. *Expert Opin Drug Saf.* 2018 Nov 21. doi: 10.1080/14740338.2019.1551356.

Bibliography

Abstracts:

1. Millichap JG, Madsen JA, Aledort LM. Febrile Seizures Indications for Continuous Anticonvulsant Therapy and Observations on Prognosis. 69th Ann Meeting Am Pediatrics Soc, May 1959.
2. Shulman NR, Marder VJ, Aledort LM, Hiller MC. Isoantibodies Against Platelets and Leukocytes. Proc Ninth Cong Int Soc Blood Transfusion, Mexico 1962; 439-447.
3. Aledort LM, Moss A. The Use of Edrophonium in the Evaluation and Treatment of Supraventricular Tachycardias. Circulation, 1964; 30: 40.
4. Aledort LM, Weed RI, Troup SB. Firefly Luciferase: A Na K Inhibited ATPase. Fed Proc, 1965; 25: 632. Presented at Physiol Sec, April 1966.
5. Aledort LM, Troup SB, Weed RI. Human platelet ATPase Activities: Relationship of Localization to Function. Am Soc Clin Invest, May 1966.
6. Aledort LM, Niemetz J. In Vitro Changes in Platelet Function Produced by Local Anesthetics. Fed Proc, 1967; 26: 759.
7. Puszkin E, Aledort L. Amino Acid Synthesis in Human Platelets. Fed Proc, 1968; 27: 253.
8. Weiss HJ, Aledort LM. Patterns of Abnormality in Patients with Prolonged Bleeding Time and in Normal Subjects after Aspirin Ingestion. Proc Twelfth Int Cong Hematol, New York. 1968.
9. Aledort LM, Gilbert H, Puszkin E. Patterns of Endogenous Serotonin Release Form Human Platelets. Blood 1969; 34: 535.
10. Puszkin E, Aledort L, Puszkin S. Isolation from Human Platelets of a Colchine-Binding Protein with Actin-like Properties. Blood 1969; 34: 525.
11. Gottlieb R, Aledort L. Auer Rods in Ulcerative Colitis. Proc Am Soc Hematol, Cleveland. 1969.
12. Gilbert HS, Aledort LM, Weiss HJ, Wasserman LR. Abnormalities of Platelet Function in Polycythemia Vera. Proc Am Soc Hematol, Cleveland. 1969.
13. Burrows L, Haimov M, Glabman S, Wong D, Bauer J, Aledort L, Severin C, Kark AE. The Obliterative Vascular Transplant Rejection Phenomenon - The Role of Platelet Aggregation. 3rd European Transplantation Proc, Hague. 1970.
14. Hepner GW, Aledort LM, Gerson CD, Cohen N, Herbert V, Janowitz HD. Inhibition of Intestinal ATPase by Diphenylhydantoin and Acetazolamide. Clin Res 1970; 18: 382.
15. Gutfreund DE, Aledort LM. Human Platelet Aggregation - A Threshold Requirement for ATP. Proc Am Soc Hematol, Puerto Rico. 1970.
16. Puszkin E, Puszkin S, Aledort L. Studies on the Metabolism of Acetyl Salicylic Acid (ASA) by Human Platelets. Blood, 36: December 1970
17. Goldman B, Aledort LM, Puszkin E, Burrows L. Cyproheptadine, a New Platelet Deaggregating Agent. Circulation, 1971; 44: 68(suppl).

18. Berger S, Puszkin E, Aledort LM. Distinction Between Action of Aspirin and Four Other Deaggregating Drugs. Proc Am Soc Hematol, San Francisco. 1971.
19. Gutfreund D, Puszkin E, Sheppa M, Aledort LM. Factors Controlling Human Platelet Ca⁺⁺ and Mg⁺⁺ Content. Proc Am Soc Hematol, San Francisco. 1971.
20. Litwak RS, Mitchess BA, Kahn M, Berger S, Aledort LM, Jurado RA, Lukban SB. Perfusion Without Donor Blood. Proc Am Assoc Thor Surg. 1972.
21. Nirmul G, Taub RN, Aledort LM, Berger S, Burrows L. Prolonged Rat Renal Allograft Survival with Cyproheptadine. Proc Ninth Cong European Dialysis Transplant Assoc. 1972.
22. Hanson JP, Repke DI, Katz AM, Aledort LM. A Troponin-Tropomyosin-like Ca⁺⁺ Sensitizing System in Human Platelets. Proc Third Cong Int Soc. Thromb Hemostas. 1972.
23. Berger S, Aledort LM, Gilbert H, Hanson J, Wasserman LR. Platelet Function Abnormalities in Polycythemia Vera. Proc Fourteenth Int Cong of Hematol. 1972.
24. Berger S, Puszkin E, Aledort LM. The Effect of Anti-Serotonin and Anti-Histamine Drugs on Platelet Function in Vitro. Proc Third Cong Int Soc. Thromb and Hemostas. 1972.
25. Benis AM, Nossel HL, Aledort LM, Leonard EF. Thrombus Formation in Flow Chambers Studied with Dogs Having Long-Term Extracorporeal Shunts. Proc Third Cong Int Soc. Thromb and Hemostas. 1972.
26. Burrows L, Haimov M, Aledort L, Leiter E, Nirmul G, Taub R, Glabman S. The Platelet in the Obliterative Vascular Rejection Phenomenon. Fourth Int Cong of the Transplantation Soc. 1972
27. Puszkin S, Puszkin E, Hanson J, Aledort LM. The Effect of ADP on the Superprecipitation of Human Platelet Thrombosthenin. Fed Proc. 1973; 32: 220.
28. Tamari Y, Puszkin E, Aledort L, Degnan TJ, Wagner N, Kaplitt MJ, Peirce C. Platelet Damage During Extracorporeal Circulation. Med Instrum 1973; 7: 81.
29. Aledort LM, Puszkin E, Hanson J, Katz AM. Control of Platelet Contraction. J Microvasc Res 1973; 6: 1.
30. Patel T, Aledort LM, Puszkin EG. Decreased Energy Supply in Platelets in Acute Myelogenous Leukemia (AML). Fed Proc 1974; 33: 336.
31. Evans B, Aledort LM. Preliminary report on the therapeutic role of epsilon amino caproic acid (EACA) for dental surgery in hemophiliacs. Proceedings of the Tenth Cong of the World Fed of Hemophil, Helsinki. 1975.
32. Aledort LM. Home Care: Its challenge and impact. Proc of the Tenth Cong of Hemophil, Helsinki. 1975.
33. Aledort LM. Factor IX and thrombosis. Proc of the Tenth Cong of the World Fed of Hemophil, Helsinki. 1975.
34. Gendelman S, Aledort LM. Intracranial meningioma in factor IX deficiency. Proc of the Tenth Cong of the World Fed of Hemophil, Helsinki. 1975.
35. Aledort LM. World use of blood products in hemophilia. Proc of the Tenth Cong of the World Fed of Hemophil, Helsinki. 1975.

36. Patel I, Ambinder E, Wasserman LR, Holland JF, Aledort LM. In Vitro and in Vivo Comparison of Single Donor Platelet and Multiple Donor-Pooled Platelet Transfusions in Leukemic Patients. Amer Soc Hematol Ann Meeting, Boston. 1976.
37. Vlachakis ND, Aledort LM. Platelet Aggregation and Plasma Catecholamines in Hypertension. Proc of the Sixth Int Cong on Thromb and Haemostas, Philadelphia. 1977.
38. Vlachakis ND, Aledort L. Platelet Survival and the Effect of Sympathetic Stimulus on Platelet Lipid Peroxidation in Hypertension. Clin Res 1977; 25: 458A.
39. Vlachakis ND, Aledort L. Platelet Aggregation in Plasma Catecholamines in Hypertension. Clin Res 1977; 25: 260A.
40. Aledort LM. The Impact of Hemophilia on Blood Utilization in the USA. Fifteenth Cong Int Soc of Blood Transfusion, Paris. 1978.
41. Hilgartner MW, Aledort LM, Goodnight SH, Lusher JM. Hypertension in Patients with Hemophilia. Report from the Cooperative Study of Spontaneously Occurring Factor VIII Inhibitors in Patients with Hemophilia. Fifteenth Cong Int Soc of Blood Transfusion, Paris. 1978.
42. Diaz MD, Harris M, Aledort LM. Case Presentation of Hemophilia A with an Associated Prolonged Bleeding Time. Am Soc of Hematol 22nd Ann Meeting, Phoenix. 1979.
43. Aledort LM for the P.A.R.I.S. Research Group. The Persantine-Aspirin Reinfarction Study. Proc of the Seventh Int Symposium on Drugs Affecting Lipid Metabolism, Milan. 1980.
44. Aledort LM, Goodnight S. Impact of Hemophilia on Product Utilization. Proc of the 18th Cong of the Int Soc of Hematol and the 16th Cong of the Int Soc of Blood Transfusion, 1980.
45. Aledort LM. The United States Experience. Workshop on Mobilizing Support for Haemophilia Care. Proc of the First Int Haemophil Conf, 14th WFH Gen Assembly, Bonn. 1980.
46. Aledort LM, Levine P, Hilgartner M, Blatt P, Spero J, Goldberg JD, Popper H, Bianchi L, Desmet V, Scheuer P, Berk P for the Ad Hoc Hemophilia Study Group (AHHSG). A Study of Liver Disease among Hemophiliacs. Am Soc of Hem, 24th Ann Meeting, San Antonio. 1981.
47. Miller CH, Vorsanger GV, Diaz M, Aledort LM. Factor VIII and Factor IX Deficiency in a Hemophilic Female. Am Soc of Hematol 24th Ann Meeting, San Antonio. 1981.
48. Diaz M, Aledort LM. Different Patterns of Hemorrhages in Factor VIII Inhibitor Patients. Am Soc of Hematol 24th Ann Meeting, San Antonio. 1981.
49. Aledort LM. Present and Future Research Challenges in Hemophilia Treatment. Proc of the 19th Cong of the Int Soc of Haematol and the 17th Cong of the Int Soc of Blood Transfusion, Budapest. 1982.
50. Hilgartner MW, Aledort LM and the Ad Hoc Liver Study Group. Current Status of Liver Disease in Patients With Hemophilia. Proc of the 19th Cong of the Int Soc of Haematol and the 17th Cong of the Int Soc of Blood Transfusion, Budapest. 1982.
51. Aledort LM: AIDS and Hemophilia. Proc of the Int Soc of Haematol European and African Div, Seventh Meeting, Barcelona. 1983.
52. Aledort LM, Cohen M, Hilgartner M, Lipton R. Treatment of Hemophiliacs with Inhibitors: Cost and Effect on Blood Resources. Symposium on Factor VIII Inhibitors, Farmington. 1983.

53. Aledort LM. Alternatives for Financing the Delivery of Comprehensive Care in Times of Places of Suboptimal Financial Conditions. Proc of the Fifteenth World Fed of Hemophil Cong, Stockholm. 1983.
54. Kerr L, Spiera H, Aledort LM. DIC as a Complication of Collagen-Vascular Disease. Northeast Regional ARA Meeting, Rhode Island. 1982.
55. Miller CH, Vorsanger GV, Diaz M, Aledort LM. Double Heterozygosity in a Hemophiliac Female: Factor VIII and Factor IX Deficiency. Am J Human Genet 1982;4:102a.
56. Aledort LM. Side Effects of Substitution Therapy. Proc of the Fifteenth World Fed of Hemophil Cong, Stockholm.1983.
57. Aledort LM. AIDS and Hemophilia. Proc of the Sixteenth World Fed of Hemophil Cong, Rio de Janeiro. 1984.
58. Mannucci P, Aledort L, Allain JP, Brackman K, Boulanger G, Fearn M, Meredith K, Cordero R, Wincott E. Comprehensive Care for Hemophilia: Task Force I Report. Proc of the Sixteenth World Fed of Hemophil Cong, Rio de Janeiro. 1984.
59. Gendelman S, Rizzo FA, Forster G, Aledort L. Seizures in Hemophilia. Proc of the Sixteenth World Fed of Hemophil Cong, Rio de Janeiro. 1984.
60. Evans BE, Aledort LM. Adjunctive Management for Surgical Manipulation in the Mouth for the Bleeding Patient. Proc of the Sixteenth World Fed of Hemophil, Rio de Janeiro. 1984.
61. Miller CH, Aledort LM, Hilgartner MW. Reproductive Choices in Hemophilic Men and Carriers: Proc of the Tenth Int Cong on Thromb and Haemostas, San Diego. 1985.
62. Isola L, Aledort LM, Forster A, Bussel J, Hilgartner M. Major Surgery in Patients with Hemophilia and von Willebrand's Disease Without Plasma Derivatives. Blood 1985; 66: 5(suppl): 1: 322a.
63. Najfeld V, Seremetis S, Sanders N, Jacobson R, Aledort L, Troy K, Arlin Z, Fialkow PJ. Origin of T-Lymphocytes in Philadelphia Chromosome (Ph) - Positive Chronic Myelogenous Leukemia (CML). Blood 1985; 66(suppl): 1: 100a.
64. Hilgartner M, Aledort LM, Bussel J. Is Marrow Suppression the First Sign of the Immune Incompetence of AIDS? Blood 1984; 64: 5(suppl): 1: 97a.
65. Hilgartner M, Aledort LM. The Use of Profilin in the Treatment of Inhibitors to Factor VIII. Blood 1984; 64: 5(suppl): 1: 256a.
66. Aledort LM. HIV Status and T Cell Subsets in Congenital Coagulation Disorders. 28th Annual Meeting, Am Soc of Hematol. Blood 1986; 86: 120a.
67. Donegan E, and the Transfusion Safety Study Group. Serum Antibody Positivity in Recipients of Anti-HIV Positive Blood. 39th Annual Meeting, Am Assoc of Blood Banks, San Francisco. Transfusion, 1986; 26: 576.
68. Gaynor S, McClure E, and the Transfusion Safety Study Group. Experience with Notification of Recipients of Anti-Human Immunodeficiency Virus Positive Transfusions. 39th Annual Meeting. Am Assoc of Blood Banks, San Francisco. Transfusion 1986; 26: 594.

69. Donegan E, Perkins H, Vyas G, and the Transfusion Safety Study Group. Morality in the Recipients of Blood in the Transfusion Safety Study. 28th Annual Meeting, Am Soc of Hematol. Blood 1986; 86: 296a.
70. Fletcher MA, and the Transfusion Safety Study Group. T4 and T8 Lymphocyte Counts in HIV Positive and HIV Negative Blood Donors. 28th Annual Meeting, Am Soc of Hematol. Blood 1986; 86: 125a.
71. Mosley JW, and the Transfusion Safety Study Group. Effect of Age on the Expression of Human Immunodeficiency Virus Infection Among Hemophiliacs. 29th Annual Meeting, Am Soc of Hematol. Blood 1987; 70: 125a.
72. Pegelow CH, and the Transfusion Safety Study Group. Effect of Human Immunodeficiency Virus Infection upon Hepatitis B Virus Antibodies in Persons with Congenital Clotting Disorders. 29th Annual Meeting, Am Soc of Hematol. Blood 1987; 70: 125a.
73. Operskalski E, and the Transfusion Safety Study Group. Transmission of Human Immunodeficiency Virus Infection to Household Contacts of Persons with Congenital Hematologic Disorders. 28th Annual Meeting, Am Soc of Hematol. Blood 1986; 86: 131a.
74. Lusher JM, Aledort LM, Hilgartner M, Mosley J, Operskalski E, and the Transfusion Safety Study Group. Transmission of Human Immunodeficiency Virus Infection to Household Contacts of Persons with Congenital Hematologic Disorders. Thromb & Haemostas. 1987; 58: 1: 510.
75. Lusher JM, Aledort LM, Sarnaik S, Mosley J, and the Transfusion Safety Study Group. HIV Status, T Cell Subsets, Blood Product Use, and Hematologic Abnormalities in Congenital Coagulation Disorders (CCD). Thromb & Haemostas. 1987; 58: 1: 510.
76. Aledort LM. AIDS and Hemophilia. Keio J of Med. 1987; 36: 128-129.
77. Aledort LM, Lipton RA, Hilgartner M. Physician-Directed Blood Product Purchasing - A Cost Efficient Health Care Delivery System. 29th Annual Meeting of the Am Soc of Hematol, Washington DC. Blood 1987; 70: 5(suppl): 1: 325a.
78. Brettler D, Forsberg A, Levine P, Aledort LM, Hilgartner M, Kasper C, Lusher J, McMillan C, Roberts H. The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients with Inhibitor Antibodies: A Multicenter US Trial. 29th Annual Meeting of the Am Soc of Hematol, Washington DC, 1987. Blood 1987; 70: 5(suppl): 1: 329a.
79. Diaz M, Aledort LM, Forster A. Reduced Recovery of Factor VIII from Viral Inactivated Concentrate. 29th Annual Meeting of the Am Soc of Hematol, Washington DC, 1987. Blood 1987; 70: 5(suppl): 1: 329a.
80. Uehlinger J, Watt R, Aledort L. Extracorporeal Immunoabsorption: An Alternative Treatment for Hemophiliacs with High-Responding Inhibitors. 29th Annual Meeting of the Am Soc of Hematol, Washington DC, 1987. Blood 1987; 70: 5(suppl): 1: 334a.
81. Gumprecht J, Babyatsky M, Conill A, Biancho J, Aledort L, Berk P. Rapid Accurate Determination of the Prothrombin Time Using a Fingerstick Method. 29th Annual Meeting of the Am Soc of Hematol, Washington DC, 1987. Blood 1987; 70: 5(suppl): 1: 375a.
82. Weiss HM, Simon R, Hubbard ML, Aledort LM. Compliance in a Comprehensive Hemophilia Center - Its Implications for Home Care. 18th Int Cong of the World Fed of Hemophil, Madrid Spain, 1988. Abstract Book 1988.

83. Aledort LM, and the Transfusion Safety Study Group. HIV and HBV Markers in Congenital Coagulation Defect (CCD) Patients. IV Int Conf on AIDS, Stockholm, June 1988. 1988; 1: 401.
84. Aledort LM, and the Transfusion Safety Study Group. HIV and HBV Markers in Congenital Coagulation Defect (CCD) Patients. Samuel Bronfman 6th Ann Research Day, New York, September, 1988.
85. Gomperts ED, Willoughby A, Hilgartner M, Hoots K, Lee M, Warrier I, Aledort L, Andes A, Eyster E, Kisker T, Parmley R, Sexauer C. Survey of Hemophilic Children: HIV Status, Growth and Development. XVIII Int Cong of the World Fed of Hemophil, Madrid Spain, 1988. Abstract Book 1988; 86.
86. Gilbert MS, Aledort LM. Musculoskeletal Infections in Hemophilia: A Developing Pattern. XVIII Int Cong of the World Fed of Hemophil, Madrid Spain. Abstract Book 1988; 31.
87. Aledort LM. The Evolution of the Hemophilic Arthropathy According to the Factor VIII Dosage. XVIII Int Cong of the World Fed of Hemophil, Madrid Spain, 1988. Abstract Book 1988; 35.
88. Aledort LM. Factor VIII Concentrates. Current Issues and Future Prospects. Symposium Co-Sponsored by FDA and NHLBI, Bethesda, Maryland, March 9-10, 1989.
89. Aledort LM. Concentrates: Meeting the Demand. Fifth Int Conf on AIDS, The Scientific and Social Challenge. Montreal, Quebec, Canada, June 1989. Abstracts 1989; Th.B.O.36: 217.
90. Killinger JF, Rosenberg PS, Goedert JJ, Aledort LM, Vaidya K, Kessler CM, Gail MH. Risk Estimates of AIDS in Hemophiliacs. Fifth Int Conf on AIDS, The Scientific and Social Challenge. Montreal, Quebec, Canada, June 1989. Abstracts 1989; W.A.P.61: 130.
91. Schwartz RS, Abilgaard C, Aledort L, Bloom A, Brackmann H, Brettler D, Dietrich S, Egli J, Fujimaki M, Fukui H, Hilgartner M, Inwood M, Kasper C, Kernoff P, Levine P, Lusher J, Mannucci P, Scharrer I. Preliminary Report of Clinical Investigation of Human Factor VIII Derived from Recombinant DNA (rFVIII). 12th ASTH Cong. Tokyo, Japan, August, 1989.
92. Transfusion Safety Study Group represented by Donegan, E. Comparison of HTLV-I/II with HIV-1 Transmission by Component Type and Shelf Storage Before Administration. 42nd Ann Meeting, Am Assoc of Blood Banks, New Orleans. Transfusion 1989; 29: S130.
93. Transfusion Safety Study Group represented by Tomasulo, PA. Human T-Cell Lymphotropic Virus Infection Among Blood Donors: Epidemiologic Pattern Compared with that of Human Immunodeficiency Virus Type I. 42nd Ann Meeting, Am Assoc of Blood Banks, New Orleans. Transfusion 1989; 29: S133.
94. Transfusion Safety Study Group represented by Busch, M. HIV-1 p-24 Antigen Screening of Male Blood Donors from High Anti-HIV-1 Prevalence Areas. 42nd Ann Meeting, Am Assoc of Blood Banks, New Orleans. Transfusion 1989; 29: S203.
95. Transfusion Safety Study Group represented by Gjerset, G. Impact of Allotypic Proteins in the Treatment of HIV-1 Infected Hemophiliacs. 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989.
96. Transfusion Safety Study Group represented by Hilgartner, M. Human T-Cell Lymphotropic Virus (HTLV) Types I/II Infection Among Persons Treated with Blood Components. 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989.

97. Transfusion Safety Study Group represented by Fletcher, MA. Effect of HTLV I/II Seropositivity on Lymphocyte Phenotypes in Blood Donors. 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989; 74: 7: 246a.
98. Transfusion Safety Study Group represented by Mosley, JW. HTLV I/II Infection of Blood Recipients and its Early Effect on Lymphocyte Subpopulations. 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989; 74: 7: 178a.
99. Aly AM, Aledort LM, Hoyer LW. Histocompatibility Antigen Patterns in Hemophilic Patients with Factor VIII Inhibitors. 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989; 74: 7: 254a.
100. Rose EH, Aledort LM. Nasal Spray Desmopressin (DDAVP) - A Simple Technique for Treatment of Mild Hemophilia A and von Willebrand's Disease. 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989; 74: 7: 254a.
101. Bussel J, Graziaon JN, Cunningham-Rundles S, Jacobs J, Aledort LM. IV Anti-D: A New Effective Treatment of HIV-Mediated Thrombocytopenia. 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989; 74: 7: 383a.
102. Transfusion Safety Group represented by Hassett J. Impact of Allotypic Proteins on Lymphocyte Subsets in the Treatment of HIV-1 Uninfected Hemophiliacs. 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989; 74: 7: 342a.
103. Schwartz RS, Abilgaard C, Aledort LM. Safety and Efficacy of Recombinant DNA Derived FVIII (rFVIII). 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989; 74: 7: 49a.
104. Driscoll MC, Aledort LM, Hilgartner MW. Factor IX Gene Mutant Detectable by Analysis of Amplified Sequences. 31st Ann Meeting, Am Soc of Hematol, Atlanta. Blood 1989; 74: 7: 254a.
105. Gjerset G and the Transfusion Safety Study (TSS). Lack of Association in Anti-HIV (+) Hemophiliacs Between Decline in CD4 and Treatment with Clotting Factor Concentrates. Track C: Epidemiology & Prevention (Th.C. 637).
106. Hilgartner M, and the Transfusion Safety Study (TSS). Fall of CD4 Lymphocytes in HIV-1 Infected Patients with Coagulation Diseases. Track C: Epidemiology & Prevention (Th.C. 638).
107. Eyster ME, Alter M, Aledort L, Matzakis A, Goedert JJ, and the Transfusion Safety Study (TSS). Heterosexual Cotransmission of Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV). Track C: Epidemiology & Prevention (Th.C. 564).
108. Seremetis S, Aledort LM, Sacks H, and the Monoclate Study Group. Differential Effects on CD4 Cell Counts of High or Intermediate Purity Factor VIII Concentrates in HIV+ Hemophiliacs: A Meta-Analysis. Blood 1990; 1624: 408a.
109. The Transfusion Safety Study Group represented by Aledort LM. Chronically Transfused (TX) Patients (Pts) Not Infected with HIV-1 by Antibody and Polymerase Chain Reaction (PCR). Blood 1990; 1566: 394a.
110. Eyster ME, Alter H, Aledort LM, Goedert JJ for the Multicenter Study of AIDS in Hemophiliacs, Penn State College of Medicine, MSMC, NIH. Cotransmission of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) from Men with Hemophilia to their Female Sexual Partners. Blood 1990; 1582: 398a.

111. Bray GL, Kroner B, Kessler C, Eyster ME, Ragni M, Cohen AR, Sprandio J, Hilgartner M, Aledort L, White III G, Andes WA, Lederman M, Lechner K, Goedert JJ. Chronic Hepatitis B Virus (HBV) Infection Is Not a Cofactor for Progression to Acquired Immunodeficiency Syndrome (AIDS) in Human Immunodeficiency Virus (HIV) Infected Hemophiliacs. *Blood* 1990; 1927: 484a.
112. Lipton RA, Aledort LM, Hilgartner M. The Physician-Directed Blood Product Purchasing Consortium During a World-Wide Shortage of Factor VIII Concentrate. *Transfusion* 1990 (Accepted).
113. Aledort LM. Simposio III: Complicaciones Del Tratamiento Sustitutivo: Infeccion VIH. *Federacion Espanola de Hemofilia Libro de Abstract. 6/26-26, 1991.*
114. Bray GL, Kroner BS, Arkin S, Aledort L, Hilgartner MW, Eyster ME, Ragni M, Goedert JJ, and the Milti-Center Study of AIDS in Hemophilia. Natural History of Inhibitor Loss in Human Immunodeficiency Virus (HIV) Infected Patients with Hemophilia A. *Thromb and Hemostas* 1991; 65: 6: 677: 98.
115. Aledort LM, Brettler D, Mannucci PM. Immune Function of Hemophiliacs Treated with Recombinant FVIII, a 1 Year Update. *Thromb and hemostas ICTH Abstracts* 1991; 65: 6: 705: 179.
116. Abildgaard CD, Harrison J, Hilgartner M, and the Recombinant Factor VIII Kogenate Study Group. Use of Recombinant Factor VIII (rFVIII) for Surgery. *Thromb and Hemostas ICTH Abstracts* 1991; 65 :6: 706: 181.
117. Lusher JM, Arkin S, Abildgaard CF, Hilgartner MH, and the Kogenate Study Group. Observations in Previously Untreated Hemophiliacs Receiving Recombinant (R) FVIII. *Thromb and Hemostas ICTH Abstracts* 1991; 65: 6: 706: 182.
118. Brackmann HH, Scharrer I, Kernoff PBA and the Kogenate Study Group. Clinical Efficacy of Recombinant FVIII (rFVIII) in Prophylaxis and Treatment of Bleeding Episodes in Hemophiliacs - a 1 Year Update. *Thromb and Hemostas ICTH Abstracts* 1991; 65: 6: 706: 183.
119. Aledort LM: DDAVP Non-Responsive von Willebrand's Patients: Is There Safe, Effective therapy? *Thromb and Hemostas ICTH Abstracts* 1991: 65: 6: 1128: 1159.
120. Seremetis S, Aledort L, Lusher J, Hilgartner M, Mannucci PM, Mariani G. Highly Purified Factor VIII Concentrates: Will We See More Inhibitors? *Thromb and Hemostas ICTH Abstracts* 1991; 65: 6: 1160: 1672.
121. Transfusion Safety Study Group (TSS) represented by Hilgartner MW. Comparison of Effect of CD4 Counts of Treatment with High and Intermediate Purity Clotting Factor Concentrates. *Thromb and Hemostas ICTH Abstracts* 1991; 65: 6: 1164: 1687.
122. Transfusion Safety Study Group (TSS) represented by Aledort LM. Relationship of CD4 Level to Progression of HIV-1 Infection. *Thromb and Hemostas ICTH Abstracts* 1991; 65: 6: 1164: 1688.
123. Pegelow CH, Calmann ME, O'Brien TA and the Transfusion Safety Group (TSS). Hepatitis C Antibody (anti-HCV) Prevalence in Transfused Congenital Anemia (CA) Patients. *Blood Abstracts* 1991; 78: 10: 1: 354a: 1405.
124. Seremetis SV, Aledort LM. Nasal Spray Desmopressin (DDAVP) - Experience in Home Care and Surgical Prophylaxis. *Blood Abstracts* 1991; 78: 10: 1: 275a:1089.

125. Seremetis SV, Kaspar CK, Kessler C, Seligsohn U, Aledort LM. A New Factor XI Concentrate: Experience in Surgical Prophylaxis. *Blood Abstracts* 1991; 78: 10: 1: 274a: 1086.
126. Bray GL, and the Recombinate Study Group: Arkin S, Courter S, DiMichele C, Gordon EM, Gruppo R, Haire W, Hilgartner M, Ingerslev J, Liu-Maruya S, McMillan C, Moncino M, Scheibel E, Shapiro A, Werner E, Gomperts E. Safety and Efficacy of Recombinant Factor VIII in Previously Untreated Hemophilia A Patients: Preliminary Results. *Blood Abstracts* 1991; 78: 10: 1: 57a: 219.
127. Abildgaard C, Brettler D, Aledort L, Kasper C, Mannucci PM, and the Kogenate Study Group. Immunologic Studies in HIV Positive and HIV Negative Hemophiliacs Receiving Recombinant FVIII (Kogenate) - A 2 Year Update. *Blood Abstracts* 1991; 78: 10: 1: 57a: 218.
128. Lusher JM, Arkin S, Kreuz W, Mannucci PM, Pearce J, and the Kogenate Study Group. Inhibitor (I) Development in Previously Untreated Hemophiliacs Receiving rFVIII (Kogenate) - Is There An Increased Incidence? *Blood Abstracts* 1991; 78: 10: 1: 57a: 217.
129. Kasper CK, Inwood M, Scharer I, Bloom A, Schwartz RS, and the Kogenate Study Group. Safety and Recombinant Factor VIII in Home Infusion. *Blood Abstracts* 1991; 78: 10: 1: 56a: 213.
130. The Transfusion Safety Study (TSS) represented by Lusher JM. Hepatitis C Virus (HCV) Transmission by Clotting Factor Concentrates (CF Con) in Current Use. *Blood Abstracts* 1991; 78: 10: 1: 355a: 1409.
131. Ragni M, Kingsley L, Belle S, Duerstein S, Seminara D, Obrams I, and the HMS Study Group. AIDS-Associated Non-Hodgkin's Lymphomas and other Malignancies in Patients With Hemophilia. *Blood Abstracts* 1991; 78: 10: 1: 358a: 1421.
132. Gertner JM, Kaufman FR, Sleeper LA, Donfield SM, Hilgartner MW, NY Hospital, Cornell Medical Center, LA Children's Hospital and the Hemophilia Growth and Development Study (HGDS). Impaired Growth and Pubertal Delay in HIV Positive Transfused Hemophiliacs. *Blood Abstracts* 1991; 78: 10: 1: 358a: 1422.
133. Kroner BL, Alvord WG, and Goedert JJ. Time of HIV-1 Seroconversion is Associated with Hemophilia Type, Continent of Residence, and Mean Annual Factor VIII Dose. *Blood Abstracts* 1991; 78: 10: 1: 358a: 1424.
134. Aledort LM. The Challenge of the Adolescent and HIV. Presented at the 20th Int Cong of the WFH, October, 1992; 170.
135. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. Clinical Experience in Treatment of Acquired FVIII Inhibitors with High Dose Intravenous Gammaglobulin (IGIV) (Gamimune®-N). Presented at the 20th Int Cong of the WFH, October, 1992; 139: 269.
136. Aledort LM. Factor VIII Concentrates: Is Purer Better? Presented at the 20th Int Cong of the WFH October, 1992; 150: 293.
137. Aledort LM. Orthopedic Outcome Study. Presented at the 20th Int Cong of the WFH October, 1992; 216: 426.
138. Mannucci PM, Abildgaard CF, Aledort LM, Lusher JM, Brettler DB, Bogdanoff DA, Schwartz RS, and the Kogenate Study Group. Immunologic Studies in HIV Positive and HIV Negative Hemophiliacs Receiving Recombinant Factor VIII - A 3 Year Update. *Blood Abstracts* 1992; 80: 10: 1: 230a: 909.

139. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A Prospective Study of Treatment of Acquired Factor VIII Inhibitors with High Dose Intravenous Gammaglobulin (IGIV). *Blood Abstracts* 1992; 80: 10: 1: 230a: 912.
140. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Inhibitors in Factor VIII Deficient Hemophilia: Comparison of Frequency Based Upon Treatment Product. *Blood Abstracts* 1992; 80: 10: 1: 231a: 913.
141. Seremetis S, Aledort LM, Bray G, Brettler D, Eyster E, Kessler C, Lusher J, Rickles F, Sacks H. A Three-Year Randomized Prospective Study of High or Intermediate Purity Factor VIII Concentrates in Asymptomatic HIV+ Hemophiliacs: Effects of Immune Function. *Blood Abstracts* 1992; 80: 10: 1: 366a: 1455.
142. Amy Shapiro and the International Factor Safety Group. Vapor Heated Intermediate-Purity Factor XI Concentrate Tested in a Safety Study Monitoring Transfusion-Related Viral Infection in Previously Untreated Hemophiliacs. 14th Cong of the Int Soc on Thromb and Haemostas, New York, 1993. *Thromb Haemostas* 1993; 69: 6: 538-1455.
143. Kasper CK, Inwood MJ, Andes WA, Aledort LM. A Clinical Study to Determine Recovery and Half-Life of Intermediate-Purity Factor IX Complex (Human) Immuno, Vapor Heated. 14th Cong of the Int Soc on Thromb and Haemostas, New York, 1993. *Thromb Haemostas* 1993; 69: 6: 538-1455.
144. Lusher J, Arkin S, Abildgaard CF, Hurst D, and the Kogenate PUP Study Group. Kogenate Treatment of Previously Untreated Patients (PUPS) with Hemophilia A: Update of Safety, Efficacy, and Inhibitor Development after Five Study Years. *Blood Abstracts* 1994; 84: 10: 1: 239a.
145. Seremetis S, Abildgaard C, Lusher J, Kasper C, Hurst D, and the Kogenate Study Group. Human Recombinant DNA-Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A: Conclusions After Five Years. *Blood Abstracts* 1994; 84: 10: 1: 239a.
146. Addiego JE Jr., Kasper C, Abildgaard C, Lusher J, Hilgartner M, Glader B, Aledort LM, Hurst D, Bray G. Increased Frequency of Inhibitors in African American Hemophilia A Patients. *Blood Abstracts* 1994; 84: 10: 1: 239a.
147. Lusher J, Arkin S, Abildgaard CF, Hurst D, and the Kogenate PUP Study Group. Recombinant FVIII (Kogenate) Treatment of Previously Untreated Patients (PUPS) with Hemophilia A: Update of Safety, Efficacy, and Inhibitor Development After Five Study Years. *Thromb and Haemostas Abstracts* 1995; 73: 6: 1012.
148. Mondorf W, Bray G, Scandella D, and the Recombinate Study Group. The Presence of Anti-Factor VIII Antibodies in Plasma Samples from Hemophiliacs with No Inhibitor Titer. *Thromb and Haemostas Abstracts* 1995; 73: 6: 1028.
149. Tuddenham EGD, Hoyer L, Hurst D, and the Kogenate Study Investigators' Group. Initial Studies of Genetic Factors Influencing Inhibitor Development in Previously Untreated Patients (PUPS) with Hemophilia Treated with Recombinant Factor VIII. *Blood Abstracts* 1995; 86: 10: 610a.
150. Lusher J, Hedner U, and the Novo Seven Investigators. Treatment of Internal Hemorrhages with rFVIIa in Patients with FVIII and FIX Inhibitor Antibodies. *Blood Abstracts* 1995; 86: 10: 611a.
151. Bohn RL, Avord J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of Factor VIII: Are the Clinical Benefits Worth the Additional Cost? *Blood Abstracts* 1995; 86: 10: 611a: 2430.

152. Gruppo R, Bray GL, Schroth P, Gompers ED, Aledort L, and the Recombinate Study Group. Transient Inhibitors in Recipients of Recombinant Factor VIII (r-FVIII): A Report from the Recombinate Study of Previously Untreated Patients (PUPS). *Blood Abstracts* 1995; 86: 10: 193a: 758.
153. Mannucci PM, Chediak J, Byrnes J, Kessler C, Marciniak E, Retzios AD, and the Alphanate Study Group. A High Purity Factor VIII Concentrate in the Treatment of von Willebrand's Disease. *Blood Abstracts* 1995; 86: 10: 192a.
154. Ragni MV, Triulzi D, Bass D, Duerstein S, and the Hemophilia Malignancy Study. Cytomegalovirus-Associated AIDS-Defining Disease (CMV-AIDS) in Hemophiliacs is Unrelated to Transfusion History. *Blood Abstracts* 1995; 86: 10: 544a: 2164.
155. Aledort LM. Women's Bleeding Disorders: Management During Pregnancy. *Haemophil* 1996; 2: 1(suppl): 55.
156. Carneiro JDA, Villaca PR, Odone Filho V, Morgante AMV, Boehm C, Cutting G, Aledort LM, Chamone DAF, D'Amico EA. Hemophilia
157. Mannucci PM, Chediak J, Byrnes J, Kessler C, Marciniak E, Retzios AD, and the Alphanate Study Group. A High Purity Factor VIII Concentrate in the Treatment of von Willebrand's Disease. 22nd World Fed of Hemophil Cong, Dublin, Ireland, 1996; 192a: 756.
158. Aledort LM, Bray GL, Schroth P, Perry MR, Gomperts ED for the Recombinate PUP Study Group. Complications of Hemophilia in Early Childhood. *Blood* 1996; 88: 10: 328a.
159. Mannucci PM, Chediak J, Byrnes J, Kessler C, Marciniak E, Hanna W, Retzios AD, and the Alphanate Study Group. A High Purity Factor VIII Concentrate in the Treatment of von Willebrand's Disease. *Blood* 1996; 99: 10: 330a.
160. Aledort LM. A National Hemophilia Organization: Does It Work? *Turkish J Haematol* 1997; 14(suppl): 3: 39.
161. Aledort LM. Von Willebrand's Disease: From the bedside to Therapy. *Turkish J Haematol* 1997; 14(suppl): 3: 51.
162. Orellana V, Aledort LM. Do protease inhibitors truly cause more bleeding in hemophiliacs? *Blood* 1997; 90: 10: 1(suppl): part 2: 108b.
163. Arkin S, Aledort LM. Infants and young PUPS (previously untreated patients) with FVIII deficiency: bleed patterns and the impact of inhibitors. *Blood* 1999; 94: 10 (Suppl. 1): 234a.
164. DiMichele D, Rothschild C, Sultan Y, Kroner B, Aledort L, and members of the ISTH FVII [sic] / IX Subcommittee. Multicenter comparison of inhibitor (INH) development on plasma-derived (PD) vs recombinant (REC) factor VIII(FVIII) in severe hemophilia A patients (sHA PTs). *Blood* 1999; 94: 10 (Suppl. 1): 238a.
165. Aledort LM, Russell AB, Gomperts ED, Bray GL, and Lee M. Safety and efficacy of recombinant FVIII preparations in the treatment of haemophilia A: a data synthesis. *Haemophilia* 2000; 6: 4: 358-359.
166. Bussel J, Aledort L, Hayward CPM, Kelton J, Lichtin A, McMillan R, Nierodzik ML, George J, Wasser J, Zumberg M, Saba H, Towell B, Gayko U, Cruickshank S, Nichol JL. A prospective cross-sectional study to characterize selected autoimmune (AI) markers and report the incidence of antithrombopoietin antibodies (α TPO) in patients with immune thrombocytopenic purpura (ITP). *Blood* 2000; 96: 11: 250a.

167. Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Avorn J. The economic impact of factor VIII inhibitors in patients with hemophilia A. *Blood* 2000; 96: 11: 434-435a.
168. Bussel JB, George JN, Kuter DJ, Wasser JS, Aledort LM, Chen M-G, Nichol JL. An Open-Label, Dose-Finding Study Evaluating the Safety and Platelet Response of a Novel Thrombopoietic Protein (AMG 531) in Thrombocytopenic Adult Patients with Immune Thrombocytopenic Purpura (ITP). *Blood* 2003; 102: 11: 86a.
169. Kuter D, Bussel JB, Aledort LM, George J, Lyons RM, Conklin GT, Lichtin AE, Nieva J, Kelly R, Chen C-F, Nichol JL. A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMB531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP). *Blood* 2004; 104: 11: 148a.
170. Aledort LM, Salama A, Kovaleva L, Robak T, Brenner B, Newland A, Davies S, Nugent DJ, Hubsch A, Andresen I, Zenker O. An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura. *Blood* 2004; 104: 11: 72b.
171. Aledort LM, White GC II, Rivard GE. Ten-Year Follow-Up of Inhibitor Induction in Previously Untreated Patients (PUPs) on Recombinate. *Blood* 2004; 104: 11: 87b.
172. Aledort LM, Goudemand J. U.S. Factor XI Patients: Is There a Safer Treatment? Yes – Hemoleven. *Blood* 2004; 104: 11: 87b.
173. Aledort LM. Are the thrombotic risks of recombinant factor VIIa and factor VIII inhibitor bypass activity equivalent? *Haemophilia* 2004; 10 (Suppl. 3): 54-55.
174. Aledort LM. Algorithms for hemophilia inhibitor patients: making therapeutic choices. *Haemophilia* 2004; 10 (Suppl. 3): 55.
175. Aledort LM. Considering adverse event costs in hemophilia care. *Haemophilia* 2006; 12 (suppl. 2): 58.
176. Aledort LM, Lyons RM, Okano G, Leveque J. Retrospective Matched Cohort Study of Immune Thrombocytopenic Purpura (ITP): Complications Related to Corticosteroid (CS) Use. *Blood* 2006; 108: 11 (Pt. 1): 940a.
177. Aledort LM, Lyons Rm, Okano G, Leveque J. The Clinical and Direct Medical Cost Burden of Splenectomy among managed Care Patients with Chronic Immune Thrombocytopenic Purpura (ITP). *Blood* 2006; 108: 11 (Pt. 2): 481b-482b.
178. Altomare I, Aledort LM. Is Homozygosity for the MTHFR C677T Mutation a Risk Factor for Miscarriage? – Likely. *Blood* 2006; 108: 11 (Pt. 2): 99b.
179. Aledort LM, MD, Lyons RM, Okano GJ, Leveque JA. Retrospective, Matched Cohort Study in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Risk Associated With Corticosteroid Use. *Blood* 2006 108 ASH Annual Meeting Abstracts JTH.
180. Gernsheimer TB, Pullarkat V, Senecal FM, Aledort LM, Kessler CM, Sanz MA, Liebman HA, Slovick FT, Kelly R, Guo M, Nichol J. Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study. *Blood* 2007; 110: 11: 8a.
181. Kuter DJ, Bussel JB, Senecal FM, Aledort LM, Kessler CM, Sanz MA, Liebman HA, Slovick FT, Kelly R, Guo M, Nichol JL. Evaluation of AMG 531 Efficacy in Nonsplenectomized Patients with

- Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study. *Blood* 2007; 110: 11: 173a.
182. Aledort LM, Coates JG. Hemophilia Treatment – A Model for Appropriate Cost Control. *Blood* 2007; 110: 11: 53b.
183. Tarantino M, Sunkara U, George J, Aledort LM, Guo M, Berger D, and Gernsheimer T. Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura. *Blood* 2008; 112: 11: 1173.
184. Bonagura A, Decristofano E, Faulds R, Rich KM, Schiavone-Grosser J, Deniz CA, and Aledort LM. The Effect of a Specialized Case Management Program On Factor Replacement Use On Patients with Bleeding Disorders. *Blood (ASH Annual Meeting Abstracts)* Nov 2012: 120: 4257.
185. Aledort LM, Oldenburg J, Santagostino E, and Yuste VJ. Rescue and Primary ITI in Children and Adults with a Single FVIII/VWF Product. *Blood (ASH Annual Meeting Abstracts)* Nov 2012: 120: 1174.
186. Michel M, Wasser J, Godeau B, Aledort L, Cooper N, Tomiyama Y, Khella M, Wang W, and Woodard P. Efficacy and Safety of Romiplostim in Patients ≥ 65 Years With Immune Thrombocytopenia (ITP) (18TH Congress of the European Hematology Association) – EHA18ABSSUB-3201(submitted 3/1/13)
187. Ferrari S, Palavra K, Gruber B, Kremer Hovinga JA, Knöbl P, Caron C, Cromwell C, Aledort L, Plaimauer B, Turecek PL, Rottensteiner H, Scheiflinger F. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura . *Haematologica*. 2013 Nov 15
188. Rangarajan S, Kessler C, Aledort L. The clinical implications of ADAMTS13 function: the perspectives of haemostasiologist. *Thromb Res*. 2013 Oct; 132(4):403-7
189. Aledort LM, High-titer inhibitors in children with hemophilia A: statistics can be used to support your point of view. *The International Monitor on Hemophilia* No 22/2014
190. Carcao M, Avila L, Aledort L, Leissinger C on behalf of the Factor Utilization expert working group of the International Prophylaxis Study Group (IPSG). Prophylaxis practices in children and adults with hemophilia A or B and inhibitors. *J Thromb Haemost* 2015; 13 (Suppl. 2):360. (poster presentation at the 25th Congress of the International Society of Thrombosis and Haemostasis, Toronto, Canada, June 22, 2015.)
191. Aledort L, Avila L, Blanchette V, Lambert T on behalf of the Factor Utilization expert working group of the International Prophylaxis Study Group (IPSG) (M. Carcao, member of). Prophylaxis in Adult Patients with Severe Hemophilia A or B without Inhibitors. *J Thromb Haemost* 2015; 13 (Suppl. 2):134. (oral presentation) at the 25th Congress of the International Society of Thrombosis and Haemostasis, Toronto, Canada, June 22, 2015.)
192. Angela M.G. Barbara, Louis M. Aledort, Prasad Mahew, Evelie Mauser-Bunschoten, Gianna F. Rivolta, Vadim Romanov, Annarita tagliaferri, Valerie Roussel-Robert, Jerzy Windyga, Alfonso Iorio. Investigating Determinants of inhibitor development to Factor VIII Molecules in previously treated hemophilia A patients. 60th scientific and standardization committee meeting of the international society on thrombosis and haemostasis

193. Aledort LM, Hemophilia Lend-Lease Program in Italy Successfully Meets Albania Factor Needs. American Society of Hematology. Accepted
194. Aledort LM, What I learned in Mumbai: Challenges. APSTH. Accepted.
195. Aledort L, Avila ML, Blanchette V, Lambert T and On behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators. Prophylaxis in adult patients with severe hemophilia A or B without inhibitors. *Journal of Thrombosis and Haemostasis* 2015, 13 (S2), # OR105, 134.
196. Carcao M, Avila M, Aledort L, Leissing C on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators. Prophylaxis practices in children and adults with inhibitors. *Journal of Thrombosis and Haemostasis* 2015, 13 (S2), # PO270-MON, 360.
197. Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissing C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators. Hemophilia prophylaxis no longer just for children without inhibitors - increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors). Accepted 57th American Society of Hematology Meeting 2015.
198. Aledort L & Ewenstein B. LTTE *New England Journal of Medicine*. Submitted 2017.
199. Booth J, Watt M, Vidal I, Milligan S, Aledort L. A Retrospective, Observational Study of Bax 855 in Clinical Practice in the United States. *Spanish National Congress of Thrombosis and Haemostasis*. 2018.
200. Aledort L, Jain N, Li N, Sangeeta K, Hagberg B, Su J. Changing the Paradigm in Hemophilia Care: Extended Half-Life (EHL) Products rFVIII Fc and rFIX Fc. American Society of Hemophilia Poster Presentation. December 2018.

Louis M. Aledort, MD, MACP

Signature _____

Date: 4-11-2019

